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EYE SCREENING IN U.S. ADULTS WITH DIABETES: EXAMINATION OF TRENDS, 
RACIAL AND ETHNIC DIFFERENCES, AND CONTRIBUTION OF MEDICAID 
EXPANSION, MEPS 2010-2017  
by 
KARON C. LEWIS 
(Under the Direction of Yelena N. Tarasenko) 
ABSTRACT 
Diabetic retinopathy (DR) is a prevalent cause of vision impairment and blindness among adults 
in the United States. Early diagnosis of DR through dilated eye examinations can reduce the risk 
of vision impairment or loss. Differences in eye examination rates by race and ethnicity have 
been suggested by prior studies emphasizing importance of increasing insurance coverage and 
access to care among minority populations. The Affordable Care Act aimed to expand health 
insurance coverage and improve access to care. This study examined trends overall and by race 
and ethnicity in eye examination rates and the contribution of Medicaid expansion on changes in 
eye examination rates among U.S. adults with diabetes living below 138% of the federal poverty 
level (FPL). This research utilized data from the 2010-2017 Medical Expenditure Panel Survey. 
Univariate and multivariable logistic regression models with post-estimation commands were fit 
to assess changes in eye examination rates overall, by race and ethnicity, and by residence in a 
state that expanded or did not expand Medicaid, while controlling for predisposing, enabling, and 
need factors, as conceptualized by the Andersen Healthcare Utilization model. Eye examination 
rates did not significantly change among non-Hispanic whites, non-Hispanic blacks, and 
Hispanics from 2010-2017. The fully adjusted model revealed no significant differences in eye 
examination rates between the three racial and ethnic subgroups and in individuals with diabetes 
 
 
living below 138% of the FPL in expansion vs non-expansion states. Between 2010 and 2017, no 
significant improvements in eye examination were noted among non-Hispanic whites, non-
Hispanic blacks, and Hispanics, and Medicaid expansion was not associated with changes in eye 
examination rates. Research on public health interventions targeting other factors that influence 
eye screening is warranted as expanding access to insurance coverage alone did not appear to 
translate into improvements in eye examinations. 
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 The global diabetes prevalence in adults aged 20-79 years is estimated to be 9.3% in 2019 
and is projected to rise to 10.9% by the year 2045 (Saeedi et al., 2019). In 2018, an estimated 
34.2 million people of all ages or 10.5% of the United States (U.S.) population had diagnosed 
diabetes. For U.S. adults 18+ years, the prevalence of diagnosed diabetes in 2018 was 13.0% 
(34.1 million adults) (Centers for Disease Control and Prevention [CDC], 2020a). The diabetes 
prevalence is projected to continue to rise over time as the U.S. population grows and ages 
(American Diabetes Association [ADA], 2018).  
Diabetes is a chronic condition characterized by high levels of blood glucose, which is a 
sugar found in many foods. When food is digested and broken down, glucose is released and 
absorbed into the intestines where it passes into the bloodstream. Insulin is a hormone made by 
the pancreas that promotes the absorption of blood glucose into various cells of the body for 
energy and storage. Diabetes develops when the body is either not able to produce insulin or is 
not able to use insulin properly (Roglic, 2016). With type 1 diabetes, the immune system 
destroys the cells in the pancreas that make insulin (National Institute of Diabetes and Digestive 
and Kidney Diseases [NIDDK], 2017a). As a result, the body cannot make insulin, glucose can 
no longer get into cells, and blood glucose levels rise above normal (NIDDK, 2017a). Type 1 
diabetes most often occurs in children and young adults but can appear at any age. The risk of 
developing type 1 diabetes may increase in individuals whose parent or sibling have type 1 
diabetes (NIDDK, 2017a). Type 2 diabetes is the most common form of diabetes and occurs 
when the body under-produces insulin or does not use insulin properly (NIDDK, 2017b). As a 





are more likely to develop type 2 diabetes if they are age 45 or older, are African American, 
Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific 
Islander, have a family history of diabetes, live a sedentary lifestyle, are overweight or obese, or 
have high blood pressure, low high-density lipoprotein cholesterol, high triglycerides, or 
depression (NIDDK, 2016). 
The continuous presence of excess blood glucose can lead to negative changes in the 
blood vessels, and people with diabetes often develop diverse vascular-related complications that 
can drastically reduce the quality of life (Boyle et al., 2010). A microvascular complication of 
diabetes, diabetic retinopathy is the most prevalent cause of vision impairment and blindness 
among working-age adults (i.e., those aged 20-74 years) in the U.S. and the fifth most common 
cause of vision impairment and blindness in the world (CDC, 2018; Cheung et al., 2010; Leasher 
et al., 2016; Mohamed et al., 2007). Diabetic retinopathy exists in several stages including early 
and severe non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy 
(PDR), and diabetic macular edema (DME) (Khandekar, 2012). Individuals with NPDR may not 
exhibit any symptoms; however, those with PDR are at risk for blindness and/or other serious 
morbidities (Khandekar, 2012). Approximately one in three people with diabetes aged 40 years 
and above has some sign of the diabetic retinopathy (CDC, 2014; Zhang et al., 2010). 
Progression from NPDR to PDR may occur over years of time. The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy (WESDR) found the incidence of PDR had increased from 0% 
during the first 5 years of having diabetes to 27.9% during years 13–14 of diabetes and remained 
stable after 15 years (Klein et al., 1984). Compared to individuals without diabetic retinopathy, 
those with diabetic retinopathy may experience a lower quality of life. A study performed in a 





patients with diabetic retinopathy when compared with those without diabetic retinopathy with 
maximum effect seen on general health, general vision and mental health (Pereira et al., 2017). 
Furthermore, as the severity and duration of retinopathy increased, the quality of life decreased 
(Pereira et al., 2017). 
One way to reduce the risk of severe vision impairment or loss resulting from diabetic 
retinopathy is through screening in the form of dilated eye examinations (ADA, 2019). Early 
detection of diabetic retinopathy through screening can reduce severe vision loss by up to 94% 
(Fathy, Patel, Sternberg, & Kohanim, 2016). In identifying the condition during screening, 
timely and appropriate vision care (e.g., laser treatment, medications, and/or surgery) can prevent 
or delay the onset of ocular morbidity, visual impairment, and blindness associated with diabetic 
retinopathy (Khandekar, 2012; Paz et al., 2006). The ADA (2019) and the American Academy of 
Ophthalmology (2019) recommend people with type 1 diabetes receive annual eye examinations 
beginning 5 years after the onset of the disease, whereas people with type 2 diabetes have an eye 
examination at onset of the disease and annually thereafter. However, in 2016, only 62.2% of 
adults with diabetes reported having an annual screening for diabetic retinopathy (CDC, 2020b).  
Problem Statement 
Diabetic retinopathy has been shown to disproportionately affect racial and ethnic 
minority populations. For example, non-Hispanic blacks and Hispanics are more likely to have 
diabetic retinopathy compared with non-Hispanic whites  (Carter et al., 1996; Golden et al., 
2012; Osborn et al., 2013). A study based on data from the 1988-1994 National Health and 
Nutrition Examination Survey (NHANES) found in adults aged 40 years and older, the presence 
of any diabetic retinopathy was 46% higher in non-Hispanic blacks and 84% higher in Mexican 





from the Veterans Affairs Diabetes Trial, macular edema was significantly more prevalent in 
Hispanics (18%) and non-Hispanic blacks (15.6%) than in non-Hispanic whites (6.3%) 
(Emanuele et al., 2009). Using 2005-2008 NHANES, a study of adults >=40 years of age with 
diabetes found non-Hispanic blacks and Hispanic individuals had a higher crude prevalence of 
diabetic retinopathy than non-Hispanic whites (38.8%, 34.0%, respectively, vs 26.4%) and a 
higher crude prevalence of vision-threatening diabetic retinopathy, defined as the presence of 
severe NPDR, PDR, or DME (9.3% and 7.3% respectively, vs 3.2%) (Zhang et al., 2010). In a 
study of 312 people who visited a Model Demonstration Unit of the Washington University 
Diabetes Research and Training Center, African Americans with type 1 diabetes were 1.86 times 
more likely to develop PDR compared to whites (Arfken et al., 1998).  
Additionally, some studies report differences in eye examination rates among racial and 
ethnic groups (Chen et al., 2014; Lu et al., 2016; Shi et al., 2014; Tran et al., 2017). A study 
based on the 2002-2013 Medical Expenditure Panel Survey (MEPS) data showed respondents of 
Asian and Hispanic ethnicity had a 49% and 15%, respectively, lower likelihood of ever having 
received a dilated eye examination when compared to non-Hispanic/non-Asian whites (Tran et 
al., 2017). Lu et al., surveyed 101 African American or Hispanic diabetic patients from a safety-
net clinic in Los Angeles to examine perceived barriers to screening (2016). Compared with 
Hispanic patients, African American patients were screened 50% less often in the previous year, 
despite reporting similar barriers to diabetic retinopathy screening (Lu et al., 2016).  
Previous studies have identified various barriers to obtaining eye examinations with lack 
of health insurance being identified as the most common barrier across studies (Ellish et al., 
2007; Lu et al., 2016; Owsley et al., 2006; Paz et al., 2006; Shi et al., 2014; Walker et al., 1997). 





et al., 2010; Rowland & Shartzer, 2008; Office of the Assistant Secretary for Planning and 
Evaluation [ASPE], 2012). Uninsured individuals are more likely to have unmet medical needs 
and fare worse in health outcomes compared to insured individuals (Clemans-Cope et al., & 
Blavin, 2012; Hadley, 2003; Institute of Medicine, 2001).  
The Affordable Care Act (ACA) aimed to extend health insurance coverage 
predominantly through the following initiatives: expansion of Medicaid eligibility to nearly all 
adults with incomes up to 138 percent of the federal poverty level (FPL) (previous eligibility was 
limited to specific low-income groups, such as the elderly, people with disabilities, children, 
pregnant women, and some parents; the eligibility varies from state to state); establishment of 
health insurance exchanges for small employers (e.g., ≥50 employees) and individuals 
purchasing private coverage with subsidies for individuals with incomes at 138-400 percent of 
the FPL; and requirement that US citizens and legal residents have qualifying health coverage or 
pay a tax penalty (Clemans-Cope et al., 2012; The Henry J. Kaiser Family Foundation [KFF], 
2012, 2020).  
Recent studies have demonstrated that racial and ethnic disparities in insurance coverage 
and access to care have been reduced since ACA implementation (Buchmueller et al., 2016; 
Chen et al., 2016; Monnette et al., 2019; ASPE, 2016). However, further research is warranted 
on whether increased insurance coverage translates into improved health practices and outcomes.  
Purpose 
The purpose of this study was to examine trends in eye examination rates among U.S. 
adults with diabetes overall and by race and ethnicity and to examine the contribution of the 





Research Questions  
 RQ1: Are there racial and ethnic disparities in eye examination rates among U.S. adults 
 (age≥18 years) with diabetes across 2010-2017? 
 RQ2: Is ACA Medicaid expansion associated with changes in eye examination rates 
 among U.S. adults with diabetes living below 138% of the federal poverty level (FPL)? 
Significance 
Racial and ethnic disparities in utilization of health care services and health outcomes 
have been well-documented in the U.S. Minority populations encompass smaller groups of 
people who may be discriminated against in society and differ from the majority population by 
race, ethnicity, religion, language or political affiliation (Humes et al., 2011). In a country that is 
predominantly white, racial minority populations in the U.S. include blacks or African 
Americans, Native Americans and Alaskan Natives, Asian Americans, and Native Hawaiian and 
Other Pacific Islanders. The largest minority ethnic group in the U.S. is Hispanics and Latinos; 
however, additional ethnic groups such as Jews and Arabs are also present in the U.S (Humes et 
al., 2011). The overarching goals of the Healthy People 2020 was to eliminate disparities, 
achieve health equity, and improve health for all groups (Office of Disease Prevention and 
Health Promotion [ODPHP], 2020a). However, achieving such goals requires a multifaceted 
approach that addresses individual-, sociocultural-, environmental-, and system-level factors. 
Through expanding access to insurance coverage, improving health care delivery, and reducing 
costs associated with care, the ACA aimed to address system-level barriers to care.  
There are varied reports in the literature regarding whether ACA implementation 
translates to improved health practices, particularly for preventive care use (Adams et al., 2018; 





experimental study of Medical Expenditure Panel Survey (MEPS) data that examined whether 
ACA was associated with increased preventive care service use among privately insured adults 
(aged 18-64 years) found ACA implementation was associated with increases in routine check-
ups and influenza vaccinations among those privately insured compared to those without 
insurance (Hong, et al., 2017). However, the ACA was not associated with changes in blood 
pressure check, cholesterol check and cancer screenings (pap smear test, mammography, and 
colorectal cancer screening) (Hong et al., 2017). A similar quasi-experimental study of MEPS 
data examined whether ACA’s free preventive care benefits were associated with a reduction in 
racial and ethnic disparities in the utilization of preventive care use. This study found that 
privately insured Hispanics and privately insured Blacks had an increased probability of 
obtaining a colonoscopy and mammogram compared to non-Hispanic whites on Medicaid. 
However, this study did not find any significant improvements for any racial or ethnic group for 
cholesterol screenings or Pap smears (Agirdas & Holding, 2018). Similar findings of ACA being 
associated with improvements in use of some preventive care services but not others were seen 
in quasi-experimental studies of U.S. women adult (19-64 years) populations (Lee et al., 2019) 
and U.S. adolescent (18-25 years) populations (Lau et al., 2019).  
Outside of system-level barriers to obtaining eye examinations, many other factors such 
as lack of knowledge regarding need for eye examination, lack of transportation, or lack of local 
optometrists or ophthalmologists can influence whether an individual with diabetes obtains an 
eye examination (Roy, 2004; Walker et al., 1997). These other factors can have a stronger 
influence on screening behavior than health insurance does; therefore, gaining health insurance 
through ACA implementation may not translate into increased eye examination rates. The 





changed over time and the ACA’s role in addressing racial and ethnic disparities in eye 
examination rates.  
Definition of Terms 
The following terms are used throughout this research: 
Diabetes- A metabolic disorder in which the body has high sugar levels for prolonged periods of 
time. May present in various forms such as type 1 (pancreas produces little or no insulin) or type 
2 (pancreas produces insufficient insulin or body does not use insulin properly). (NIDDK, 
2017a) 
Diabetic retinopathy- A microvascular complication of diabetes that affects the eyes. (Mayo 
Clinic, 2018) 
Non-proliferative diabetic retinopathy (NPDR)- A stage of diabetic retinopathy that is 
characterized by leaky blood vessels. (Khandekar, 2012) 
Proliferative diabetic retinopathy (PDR)- A stage of diabetic retinopathy that is characterized by 
growth of new blood vessels on the retina. (Khandekar, 2012) 
Vision-threatening diabetic retinopathy- Includes severe non-proliferative diabetic retinopathy, 
proliferative diabetic retinopathy, and diabetic macular edema. (Zhang et al., 2010) 
Diabetic macular edema (DME)- May accompany any stage of diabetic retinopathy and is 
characterized by fluid buildup in the macula which is the part of the retina that controls detailed 
vision abilities. (Khandekar, 2012) 
Vision impairment- Defined as a functional limitation of the eye or eyes that cannot be corrected 
with standard glasses or contact lenses and reduces a person's ability to function at certain or all 
tasks. (National Academies of Sciences, Engineering, and Medicine [NASEM], 2016) 





Dilated eye examination- Physical examination of the eyes that involves the administration of 
eye drops to dilate pupils in order to allow more light into the eye. During eye examination, 
optometrist/ophthalmologist assess for abnormalities with the anatomy and functioning of the 
eye(s). (National Eye Institute, 2019) 
Racial minority- A group of people from a different race living in a country or area where the 
majority of people are of a different race. (Pollard & O'Hare, 1999) 
Ethnic minority- A group of people from a different nationality or ethnicity living in a country or 
area where the majority of people are of a different nationality or ethnicity. (Pollard & O'Hare, 
1999) 
Health disparity- A particular type of health difference that is closely linked with economic, 
social, or environmental disadvantage. Health disparities adversely affect groups of people who 
have systematically experienced greater social or economic obstacles to health based on their 
racial or ethnic group, religion, socioeconomic -status, gender, age, or mental health; cognitive, 
sensory, or physical disability; sexual orientation or gender identity; geographic location; or 
other characteristics historically linked to discrimination or exclusion. (ODPHP, 2020a)  
Health insurance coverage- Coverage that provides for the payments of benefits as a result of 
sickness or injury. It includes insurance for losses from accident, medical expense, disability, or 
accidental death and dismemberment (Caxton, 2017) 
Affordable Care Act- Health reform legislation signed into law by President Barack Obama in 
March 2010 that extended health insurance coverage through the expansion of Medicaid 
eligibility and through establishment of health insurance exchanges for small employers  (e.g., 
≥50 employees) and individuals purchasing private coverage (Clemans-Cope, 2012; KFF, 2012, 





Medicaid expansion- Expansion of Medicaid eligibility to nearly all adults with incomes up to 
138 percent of the federal poverty level (FPL). Previous eligibility varied from state to state but 
was limited to specific low-income groups, such as the elderly, people with disabilities, children, 
pregnant women, and some parents. (KFF, 2012, 2020) 
Federal poverty level- Defined as the minimum annual income required to avoid living in 






CHAPTER 2-LITERATURE REVIEW 
Chapter 2 provides an extensive review of the literature and research on diabetic 
retinopathy, eye screening,  and the Affordable Care Act. The chapter is divided into sections 
that include an overview of diabetic retinopathy including disease burden, screening and 
treatment recommendations and costs, factors influencing screening, conceptual framework, the 
role of health insurance in addressing racial and ethnic disparities, and an overview of the 
Affordable Care Act. 
Out of all the human senses, vision is the most highly developed. It plays an important role 
in the way humans interact with the environment around them. It is important for learning skills 
and devices, moving around, and protecting us from danger (American Academy of 
Ophthalmology, 1987). Therefore, the loss of vision can greatly impact the affected individuals, 
as well as their friends and family. The weakening or loss of vision can impair an individuals’ 
ability to completely care for themselves and subsequently, can result in the need for a caretaker. 
Vision loss can affect many aspects of an individual’s life such as the quality of life (QOL), 
independence, mobility, mental health, cognition, social function, employment, and educational 
attainment (National Academies of Sciences, Engineering, and Medicine, 2016). In a study using 
Behavioral Risk Factor Surveillance System (BRFSS) data from 22 states, researchers examined 
health-related QOL among individuals ages 40 to 64 years by visual impairment status and found 
the percentage of individuals reporting life dissatisfaction, fair or poor reported health, physical 
and mental unhealthy days, and days of limited activity increased as the self-reported severity of 
vision impairment increased (Crews et al., 2016; National Academies of Sciences, Engineering, 





loss and then decreased more quickly as measures of visual field defects increased (Rein et al., 
2007).  
Vision impairment can create challenges for any individual, and the diabetes population is 
no exception as individuals with diabetes are susceptible to a plethora of vision-related 
complications. Not being able to see well can affect various vision-reliant tasks for individuals 
with diabetes. Tasks required for diabetes management such as self-care (e.g., foot checks, 
checking blood glucose levels, preparing nutritious meals) and transportation (e.g., getting to and 
from clinic visits) can be greatly hindered by impaired vision (NASEM, 2016). Additionally, 
vision impairment can affect the individual’s ability to be compliant with medication adherence 
and management (e.g., reading pill bottles, self-administering insulin injections or eye drops). 
Therefore, individuals with diabetes who develop vision loss experience more challenges to 
successfully managing their condition (NASEM, 2016). Furthermore, individuals with diabetes 
tend to suffer from coexisting morbidities (e.g., obesity, cardiovascular disease) that can further 
worsen their health, and are at risk for developing several different complications including 
diabetic retinopathy.  
Diabetic Retinopathy 
Epidemiology and Risk Factors 
Diabetic retinopathy is a common complication of both type 1 and type 2 diabetes. To 
examine the global prevalence and major risk factors of diabetic retinopathy, Yau et al. (2012) 
performed a pooled meta-analysis of 35 population-based studies conducted from 1980-2008 in 
the U.S., Asia, Australia, and Europe. Based on the findings of this analysis, the overall global 
prevalence of any diabetic retinopathy (defined as presence of NPDR, PDR, DME, or any 





and 6.8%, respectively. Pooled analysis of the studies found that the age-standardized prevalence 
of any diabetic retinopathy was highest among African Americans and lowest among Asians. 
Longer diabetes duration, higher blood pressure, higher HbA1c levels, and type 1 diabetes were 
associated with higher prevalence of diabetic retinopathy (Yau et al., 2012). However, studies 
have shown that maintaining optimal glycemic levels, blood pressure levels, and serum lipid 
levels can reduce the risk or slow the progression of diabetic retinopathy (Chew et al., 2014; 
Estacio et al., 1998; Klein, 1995; Leske et al., 2005). 
At present, a national surveillance system for reporting diabetic retinopathy exists neither 
in the U.S. nor in other countries. The most current national estimate of diabetic retinopathy 
prevalence comes from the National Health and Nutrition Examination Survey (NHANES). 
Using data from the 2005-2008 NHANES, Zhang et al. (2010) estimated the prevalence of 
diabetic retinopathy and vision-threatening diabetic retinopathy (i.e., defined as the presence of 
severe NPDR, PDR, or DME) among people with diabetes aged 40 years and older was 28.5% 
and 4.4%, respectively. The prevalence among the overall U.S. population during that time 
period was 3.8% for diabetic retinopathy and 0.6% for vision-threatening diabetic retinopathy 
(e.g., severe NPDR, PDR, and DME). Significant risk factors for diabetic retinopathy that were 
identified included male sex, higher hemoglobin A1c (HbA1c) level, longer duration of diabetes, 
and higher systolic blood pressure (Zhang et al, 2010). 
Another population-based study based on a regional cohort was conducted to examine the 
incidence of diabetic retinopathy. A longitudinal study, the Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) consisted of a sample of patients with diabetes who received 
primary care in an 11-county area in southern Wisconsin from 1979 to 1980 (Klein et al., 1998). 





assessed at baseline and followed for 4, 10, 14, and 25 years. Numerous reports regarding the 
incidence and progression of diabetic retinopathy and DME have been generated from the study. 
In a WESDR report of individuals with type 1 diabetes, the 14-year incidence of any diabetic 
retinopathy was 95.9% and the 14-year incidence of DME was 26.1% (Klein et al., 1998). For 
patients with diabetic retinopathy at baseline, 36.8% had progressed to PDR (Klein et al., 1998). 
Women, individuals with higher HbA1c, and individuals with higher diastolic blood pressure 
were at greater risk for diabetic retinopathy progression. Individuals with higher HbA1c, with 
higher systolic and diastolic blood pressures, and with hypertension and proteinuria were at 
higher risk for developing PDR. (Klein et al., 1998). Factors associated with increased incidence 
of DME included severe baseline retinopathy, higher HbA1c at baseline, and presence of gross 
proteinuria at baseline. In subgroup analysis, the study assessed the relationship between the age 
and duration of diabetes at baseline and the 14-year progression of any diabetic retinopathy, 14-
year progression to PDR, and 14-year incidence of DME. A significant inverse relationship was 
found between age at baseline examination and progression of any diabetic retinopathy with the 
highest rate found in individuals ≤19 years of age and the lowest rate found in individuals ≥35 
years of age. The 14-year progression to PDR was found to be significantly associated with the 
duration of diabetes at baseline. Persons with ≥10 years of diabetes at baseline were 1.97 times 
more likely to develop PDR and DME over the 14 years follow-up compared to persons with 
<10 years of diabetes at baseline (Klein et al, 1998). The study did not include subgroup analysis 
by race and ethnicity. 
Disease Burden 
Diabetic retinopathy is recognized as a major cause of blindness and visual impairment 





Leasher et al. (2016) conducted a meta-analysis of global population-based studies that included 
data from 1990-2010. Some of the areas represented in the study included Pacific Asia, 
Australasia, Caribbean, Central, Eastern, and Western Europe, Andean, Central, Southern, and 
Tropical Latin America, Oceania, North American, and Sub-Saharan Africa. Analyses revealed 
that diabetic retinopathy accounted for 2.6% (833,690) of blindness and 1.9% (3.7 million) of 
visual impairment (Leasher et al., 2016). Diabetic retinopathy-related blindness increased by 
27% and diabetic retinopathy-related visual impairment increased by 64% from 1990 to 2010. 
Further analysis revealed that of all global blindness causes, the percentage caused by diabetic 
retinopathy increased from 2.1 in 1990 to 2.6% in 2010 (Leasher et al., 2016). 
Although diabetic retinopathy is primarily associated with causing visual impairment and 
blindness, it can also be an indicator for other systemic vascular complications. Findings from 
the Framingham Heart and Eye Study indicated individuals with diabetes who had microvascular 
disease (e.g., diabetic retinopathy) were more likely to have macrovascular disease (e.g., 
cardiovascular disease) (Hiller et al., 1988). Both NPDR and PDR have been linked with 
conditions such as stroke, coronary heart disease, heart failure and nephropathy (Wong et al., 
2001). Furthermore, diabetic retinopathy has been associated with an increased risk of mortality, 
particularly in individuals with cardiovascular risk factors (Cheung & Wong, 2008). In a pooled 
analysis of 17 prospective, observational studies, results revealed that in patients with type 2 
diabetes, the odds for all-cause mortality and/or cardiovascular events were 2.34 times as high 
for patients with diabetic retinopathy compared to patients without diabetic retinopathy. 
Similarly, for patients with type 1 diabetes, the odds for all-cause mortality and/or cardiovascular 
events were 4.1 times as high for patients with diabetic retinopathy compared to patients without 






As diabetic retinopathy can progress with few or no visual symptoms, it is important that 
individuals with diabetes receive adequate eye screening for early detection and subsequent 
intervention. The aim of early detection through screening is to discover and treat conditions 
which have already produced pathological change, but which have not reached a stage where 
medical aid has been sought spontaneously (Wilson et al., 1968). Diabetic retinopathy is optimal 
for screening because it is asymptomatic until advanced, highly prevalent, relatively easy to 
detect, and confined to a well-defined population (people with diabetes) (Wong et al., 2016). 
Furthermore, screening methods for diabetic retinopathy are relatively inexpensive, non-
invasive, and there are clear treatment modalities for treating both early stage diabetic 
retinopathy and DME that can prevent further progression and subsequent harm (ADA, 2019; 
Wong et al., 2016). Research has shown that screening is effective in detecting diabetic 
retinopathy and preventing blindness (ADA, 2019; Ding & Wong, 2012; Fong et al., 2001; 
Singer et al., 1992; Solomon et al., 2017).  
For adults with type 1 or type 2 diabetes, the ADA makes the following screening 
recommendations: 
 Adults with type 1 diabetes should have an initial dilated and comprehensive eye 
examination by an ophthalmologist or optometrist within 5 years after the onset of 
diabetes.  
 Patients with type 2 diabetes should have an initial dilated and comprehensive eye 






 If there is no evidence of retinopathy for one or more annual eye exam and 
glycemia is well controlled, then exams every 1–2 years may be considered. If 
any level of diabetic retinopathy is present, subsequent dilated retinal 
examinations should be repeated at least annually by an ophthalmologist or 
optometrist. If retinopathy is progressing or sight-threatening, then examinations 
will be required more frequently  
 Telemedicine programs that use validated retinal photography with remote 
reading by an ophthalmologist or optometrist and timely referral for a 
comprehensive eye examination when indicated can be an appropriate screening 
strategy for diabetic retinopathy (ADA, 2019, p. 129). 
Treatment 
The purpose of diabetic retinopathy screening is to identify individuals who may be at 
increased risk for developing a visual impairment or vision loss. Timely identification of signs 
and symptoms of diabetic retinopathy reduces an individual’s chances of worsening the 
condition through appropriate treatment. Current treatments for diabetic retinopathy including 
laser photocoagulation and anti-vascular endothelial growth factor (anti-VEGF) injections can 
reduce the risk of vision loss through disease regression. Panretinal photocoagulation for PDR 
involves placing laser burns over the entire retina to promote regression and arrest progression of 
retinal neovascularization (Cheung et al., 2010). In a clinical trial of over 1,758 patients with 
PDR, the Diabetic Retinopathy Study (DRS) found panretinal photocoagulation reduced the risk 
of severe visual loss by 50% over 5 years ("Photocoagulation treatment of proliferative diabetic 
retinopathy. Clinical application of Diabetic Retinopathy Study [DRS] findings, DRS Report 





of 3,711 patients with less severe diabetic retinopathy, the Early Treatment Diabetic Retinopathy 
Study (ETDRS) found early administration of the therapy reduced the risk of progression to PDR 
by 50% ("Focal photocoagulation treatment of diabetic macular edema. Relationship of 
treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS 
report no. 19. Early Treatment Diabetic Retinopathy Study Research Group," 1995). For 
treatment of DME, photocoagulation is used to target individual leaky blood vessels near the 
macula. The ETDRS found a 50% reduction in the risk of visual loss from clinically significant 
DME after macular laser treatment ("Focal photocoagulation treatment of diabetic macular 
edema. Relationship of treatment effect to fluorescein angiographic and other retinal 
characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study 
Research Group," 1995).  
Although laser photocoagulation is considered the standard ocular treatment for diabetic 
retinopathy and DME, ocular injection of anti-VEGF has been introduced as an alternative 
treatment method. A randomized clinical trial of 305 adults with PDR demonstrated intravitreal 
injections of an anti-VEGF agent, specifically ranibizumab, resulted in visual acuity outcomes 
that were not worse than outcomes observed in patients treated with panretinal photocoagulation 
at 2 years of follow up (Writing Committee for the Diabetic Retinopathy Clinical Research et al., 
2015). Additional outcomes observed for the ranibizumab treatment group were less peripheral 
visual field loss, fewer vitrectomy surgeries for secondary complications from their proliferative 
disease, and a lower risk of developing DME (ADA, 2019; Writing Committee for the Diabetic 





 In cases where NPDR, PDR or DME is detected through screening, patients should be 
referred to an ophthalmologist who is knowledgeable and experienced in the management of 
diabetic retinopathy (ADA, 2019). The ADA provides the following guidelines for treatment: 
 Promptly refer patients with any level of macular edema, severe nonproliferative 
diabetic retinopathy (a precursor of proliferative diabetic retinopathy), or any 
proliferative diabetic retinopathy to an ophthalmologist who is knowledgeable 
and experienced in the management of diabetic retinopathy.  
 The traditional standard treatment, panretinal laser photocoagulation therapy, is 
indicated to reduce the risk of vision loss in patients with high-risk proliferative 
diabetic retinopathy and, in some cases, severe non-proliferative diabetic 
retinopathy.  
 Intravitreous injections of anti–vascular endothelial growth factor ranibizumab are 
not inferior to traditional panretinal laser photocoagulation and are also indicated 
to reduce the risk of vision loss in patients with proliferative diabetic retinopathy.  
 Intravitreous injections of anti–vascular endothelial growth factor is indicated for 
central-involved diabetic macular edema, which occurs beneath the foveal center 
and may threaten reading vision. (ADA, 2019, p 129) 
Costs 
 Studies have shown that diabetics with retinopathy have significantly higher medical 
costs than those without retinopathy (Schmier et al., 2009; Zhang et al., 2017). A recent study 
performed in Singapore of adults (21-90 years) with type 2 diabetes found that the median of 
total costs in individuals with diabetic retinopathy was significantly higher than that in 





diabetic retinopathy with cost ratios of 1.1, 1.8, 2.0, and 2.3 for mild, moderate, severe NPDR, 
and PDR, respectively, relative to non-diabetic retinopathy respectively (Zhang et al., 2017). A 
U.S. study that analyzed Medicare claims data of diabetic beneficiaries with NPDR or PDR to 
diabetic beneficiaries with no evidence of diabetic retinopathy reported similar findings (Schmier 
et al., 2009). Their study of diabetic adults (≥65 years) found that the annual average costs for 
both all care and ophthalmic care were significantly higher for beneficiaries with NPDR or PDR 
compared to beneficiaries without diabetic retinopathy (Schmier et al., 2009). They also found 
that average payments for all care and for ophthalmic care were substantially higher for PDR 
cases compared to NPDR cases (Schmier et al., 2009). Early detection and treatment of diabetic 
retinopathy has the potential to significantly reduce diabetes-related medical costs. 
 Many studies have used computer simulation modeling to evaluate the cost-effectiveness 
of screening and treatment for diabetic retinopathy (Crijns et al., 1999; Javitt et al., 1994; Javitt 
et al., 1996; Jones et al., 2010; Polak et al., 2003). Using data from U.S. population-based 
epidemiological studies and clinical trials, along with data on federal budgetary costs of 
blindness, Javitt et al. (1994) estimated the current and potential federal savings resulting from 
the screening and treatment of and treatment of retinopathy in patients with type II diabetes. 
Screening and treatment of diabetic retinopathy resulted in projected savings of $247.9 million to 
the federal budget and 53,986 person-years of sight (Javitt et al, 1994). This study projected that 
enrolling each additional person with type II diabetes into currently recommended 
ophthalmological care would result in an average net savings of $975/person (Javitt et al, 1994). 
 Additional studies have also examined the cost-effectiveness of diabetic retinopathy 
screening and treatment in terms of prevented blindness or years of avoided sight loss. A study 





20,000 patients. The study found that in younger onset (<25 years) patients, screening reduced 
the prevalence of blindness by 52%; however, little benefit was seen from screening in terms of 
reduction in blindness later onset (>75 years) patients (Crijns et al., 1999). In a similar study that 
modeled the cost-effectiveness of ophthalmological care (screening and treatment) in relation to 
the progression of diabetic retinopathy, different scenarios of ophthalmological screening were 
used to determine their cost-effectiveness in preventing blindness due to diabetic retinopathy 
(Polak et al., 2003). Also performed in the Netherlands, the study found that screening was most 
cost-effective in patients with earlier onset of diabetes. For patients with age of onset of 15 years, 
the simulation model found that those who received screening frequently (i.e., 1 year if no 
diabetic retinopathy present, twice a year if any diabetic retinopathy present, and 4 times a year if 
ME or PDR present) had a lifetime sight gain of 532 years/1000 patients when compared to those 
who did not receive screening. This rate diminished with increasing age in those with an onset of 
35 years, 50 years, and 65 years and their lifetime sight gain was 125 years/1000 patients, 63 
years/1000 patients, and 16 years/1000 patients, respectively (Polak et al., 2003).   
Factors Influencing Diabetic Retinopathy Screening 
 As with any health behavior, there are many factors that can influence whether an 
individual obtains diabetic retinopathy screening. The literature reports mixed findings on race 
and ethnicity as a contributing factor to diabetic retinopathy screening. In adjusted analyses of 
2002-2013 MEPS data, Tran, et al. (2017) found that the non-Hispanic whites were more likely 
than Asians to report having an eye examination but did not find a significant difference in eye 
examination rates between non-Hispanic whites and other minority groups (i.e., Hispanics and 
non-Hispanic blacks). Contrastingly, Chen et al. (2014) found in adjusted analyses that both non-





eye examination. Shi et al. (2014) reported the opposite in that non-Hispanic whites were more 
likely to have dilated eye examinations compared to minority populations (i.e., all other non-
Hispanic whites including blacks, Hispanics, American Indian/Alaska native, Asian, native 
Hawaiian/Pacific islander, or multiple races). 
 In addition to race and ethnicity, other sociodemographic factors such as age, education, 
sex, marital status, income and insurance status have also been associated with diabetic 
retinopathy screening. Population-based studies of  2002-2009 MEPS data (Shi et al., 2014), 
2001-2010 BRFSS data (Chen et al., 2014), and 2014-2015 MEPS data (Monnette et al., 2019) 
found that older individuals (aged ≥45 years) were more likely to report receiving an eye 
examination compared to younger individuals (aged<45 years). Education level was also shown 
to influence screening as the likelihood of obtaining an eye examination increased with 
increasing levels of education. Individuals with no high school diploma were less likely to obtain 
an eye examination compared to individuals with a high school diploma (Chen et al, 2014; 
Monnette et al., 2019; Shi et al. 2014; Tran et al., 2017), bachelor’s degree (Monnette et al., 
2019; Tran et al., 2017), or professional degree (Tran et al., 2017). Women and 
married/partnered individuals were also more likely to report receiving an eye examination 
(Chen et al., 2014; Monnette et al., 2019; Tran et al., 2017). Lastly, additional socioeconomic 
factors found to be associated with eye examination were income ≥400 of the federal poverty 
level (FPL) (Tran et al., 2017) or income >$50,000 (Chen et al, 2014) and having either private 
or public insurance (Chen et al, 2014; Monnette et al., 2019; Shi et al. 2014; Tran et al., 2017). 
Other health and health care-related factors found to be positively associated with eye 
examinations were having a usual provider (Chen et al., 2014; Tran et al., 2017) and insulin use 





retinopathy prevalence and thus, might influence eye examination utilization (ADA, 2019; 
Solomon et al., 2017; Zhao et al., 2014).  
In addition to factors that may increase the likelihood that an individual obtains diabetic 
retinopathy screening, several barriers to screening have also been identified. While there are 
many approaches to categorizing barriers, in a review of the literature, Nsiah-Kumi, Ortmeier, 
and Brown (2009) identified patient-, provider-, and health care system-related barriers to 
screening decisions. A common patient-level theme identified in the literature was a lack of 
knowledge and understanding of diabetic retinopathy, diabetic retinopathy screening, and 
diabetic retinopathy treatment (Hartnett, Key, Loyacano, Horswell, & Desalvo, 2005; Nsiah-
Kumi et al., 2009; Schoenfeld, Greene, Wu, & Leske, 2001; Walker et al., 1997). Studies found 
that patients did not understand the rationale for obtaining annual eye exams (Hartnett et al. 
2005) and did not believe they were necessary (Roy, 2004; Schoenfeld et al., 2001). Additional 
barriers identified were that patients had never been told by their physician to have an annual eye 
exam (Roy, 2004; Walker et al., 1997) or patients had been unaware of or lacked eye-related 
symptoms (Hartnett et al. 2005; Roy, 2004; Walker et al., 1997). Affordability and being too 
busy to schedule an appointment were also identified as barriers to obtaining an eye examination 
(Hartnett et al., 2005; Moss et al., 1995; Roy, 2004; Walker et al., 1997). For non-English-
speaking Hispanics, for example, language barriers, and access to specialty care have been 
identified as obstacles to obtaining recommended screening (Kirk et al., 2008; Nsiah-Kumi et al., 
2009). 
Along with patient factors, provider-related factors have also been identified as barriers 
to diabetic retinopathy screening. These include lack of awareness about screening guidelines 





screening completion rates include inadequate patient education (Moss et al., 1995; Walker et al., 
1997), poor patient-physician communication (Chin et al., 2001; Hartnett et al., 2005), and 
insufficient appointment time with providers (Chin et al., 2001; Nsiah-Kumi et al., 2009). In a 
population-based study of patients and their physicians, Mukamel et al. (1999) explored various 
barriers to compliance with diabetic retinopathy screening guidelines. A significant factor 
identified that influenced the probability of screening was the average number of primary care 
physician visits each patient had. For patients who visited their primary care physician more 
often, the probability of screening was significantly higher, suggesting that more contact with the 
primary care physician may lead to more time for interaction and education of the patient 
(Mukamel et al., 1999; Nsiah-Kumi et al., 2009). 
System-level factors include lack of insurance coverage, long wait times for 
appointments, and difficulties in scheduling appointments (Hartnett et al., 2005; Nsiah-Kumi et 
al., 2009; "Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application 
of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic 
Retinopathy Study Research Group," 1981). In a study of a Latino population, those with lack of 
health care coverage were twice as likely to not have visited the doctor in the previous year nor 
have had an eye exam (Varma et al., 2004). Additionally, understaffing and high turnover of 
specialized physicians such as optometrists and ophthalmologists contribute to poor screening 
completion (Silver et al., 2006).  
In Shi’s et al. study (2014), health insurance coverage was identified as a strong predictor 
for receiving an eye examination. However, not all types of health insurance coverage are 
created equal in that some plans contain benefits that others do not. Lack of certain benefits, such 





examinations, can directly affect an individual’s self-monitoring behavior of obtaining 
preventive screenings. In Shi et al. study (2014), the researchers observed insurance coverage 
decreased over the years with minorities being affected to a larger degree than non-Hispanic 
whites. However, even within the insured population, minorities still obtained eye examinations 
to a lesser extent than non-Hispanic whites. Hence, it is possible that insurance coverage alone 
may not fully address the racial and ethnic disparity seen in eye examination rates. The authors 
surmise that in addition to health insurance coverage, other factors could contribute to the 
disparities seen in diabetic retinopathy screening in this study. For example, patient’s attitudes 
toward screening or referral by a health care provider are factors that can affect the uptake of 
diabetic retinopathy screening services (Van Eijk et al., 2012). Additionally, the geographical 
distribution of ophthalmologists and optometrists may also affect diabetic retinopathy screening 
as in the areas with fewer ophthalmologists and optometrists, fewer dilated eye examinations 
may be performed (Chou et al., 2012; Gable et al., 2000).  
Further supporting this idea that other factors can contribute to screening, a cross-
sectional study of insured veterans at 21 Veteran Affairs’ facilities reported that a significantly 
lower percentage of black patients had received a dilated eye examination in the past year 
compared to white patients (Heisler et al., 2003). Even after adjusting for several covariables 
(patients’ age, education, income, insulin use, diabetes self-management, duration, severity, 
comorbidities, and health services utilization), the racial differences in receipt of eye 
examinations persisted (Heisler et al., 2003). Considering that all participants in the study were 
insured, these findings highlight the need to examine other health care system factors when 
examining racial and ethnic differences in rates of eye exams. In this study, nearly all the racial 





at facilities with poorer performance on that quality measure suggesting that improving the rate 
of screening at low-performing facilities may improve racial disparities in eye care (Heisler et 
al., 2003). 
Andersen Healthcare Utilization Model  
The multitude of factors that have been associated with screening have been categorized 
in different ways. For example, prior studies have characterized them as patient-level, provider-
level or system-level factors. One approach to characterizing influencing factors is through the 
Andersen Healthcare Utilization model. The model was created by Ronald Andersen in 1950 and 
has been used in health behavioral studies to predict and explain use of health services. The 
model suggests that health service utilization is determined by the individual’s propensity to use 
or not use services (predisposing factors), facilitators or impediments to use of service (enabling 
factors) and needs or perceived need for care (need factors) (Andersen et al., 2013; Lee et al., 
2018). The model has evolved over time to include contextual determinants of health services 
utilization which can include organization and provider-related factors as well as community 
characteristics (Andersen et al., 2014).  
The variables that were considered to operationalize the Andersen Healthcare Utilization 
model are depicted in Figure 2.1. Consistent with the literature review provided earlier in this 
chapter, predisposing factors explored in this study will include age, sex, marital status, and 
education. Enabling factors will include economic status as a percentage of the federal poverty 
level, whether individual has a usual source of care, and insurance status. Need factors will 
include duration of diabetes and insulin use. As depicted in Figure 2.1, the predisposing variables 
impact enabling variables, which impact need variables and all three constructs influence the 








Figure 2.1. Conceptual Framework: Andersen’s Healthcare Utilization Model  
Through its various provisions that aimed to expand insurance coverage, the ACA was 
forecasted to increase rates of health insurance coverage and reduce financial barriers to service 
use among millions of at need Americans. Since racial and ethnic minorities are more likely to 
be uninsured and lack access to care including preventive screenings (Agency for Healthcare 
Research and Quality [AHRQ], 2011; 2017), ACA implementation should have consequently 
lessened some of these disparities. Therefore, this study will examine the effects of the ACA 
while controlling for predisposing, enabling, and need factors. 
The Role of Health Insurance in Addressing Racial and Ethnic Disparities 
Health insurance is an important resource for people because it can increase their ability 
to obtain necessary medical care and protect them against financial burdens that come with 
unexpected medical events. This is particularly true for racial and ethnic minorities who 
historically have experienced poorer overall health status compared to whites (Heckler, 1985). 
As health insurance is a fundamental component in obtaining positive health outcomes, 
particularly in minority populations, much research has been done to understand the impact 
health insurance coverage may have in reducing disparities in health services. In a review of the 
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literature, Lillie-Blanton and Hoffman (2005) identified articles that answered the question: How 
much of racial and ethnic disparities in access to care can be explained by differences in health 
insurance status? The review included original research studies that 1) compared whites to a 
specific racial and ethnic group (blacks or Hispanics); 2) measured the effects of racial and 
ethnic differences in social, economic, or health system factors that may contribute to disparities 
in access to health care; and (3) quantified the contribution of racial and ethnic differences in 
health insurance on disparities in access to care (Lillie-Blanton & Hoffman, 2005). Four studies 
were identified that applied regression-based methods so that multiple factors could be isolated 
to determine each factor’s contribution to racial and ethnic disparities in access to care (Lillie-
Blanton & Hoffman, 2005). The studies used several measures of access; however, the measure 
of access that was common across all four studies was whether the individual had a usual source 
of care. Therefore, the researchers used this as their measure of health care access (Lillie-Blanton 
& Hoffman, 2005).  
Overall, the studies found both Hispanics and blacks were significantly less likely than 
whites to have a usual source of care. However, a larger access gap was seen between Hispanics 
and whites than between blacks and whites. Across all four studies, the access gap between 
Hispanics and whites ranged between 15 to 16 percentage points, and the access gap between 
blacks and whites ranged between 4.4 to 8.4 percentage points (Hargraves & Hadley, 2003; 
Waidmann & Rajan, 2000; Weinick et al., 2000; Zuvekas & Taliaferro, 2003). In examining the 
contribution of insurance coverage in explaining the access gap, health insurance consistently 
explained a significant share (23-33%) of the Hispanic-white access difference and was the 
single largest observable factor in all but one study where both health insurance and income 





insurance explained 24 to 42% of the black-white access difference. In the Weinick et al. (2000) 
study, insurance only accounted for 5%, whereas income accounted for 41% of the access gap. 
The only other factor that contributed a sizable share to the black-white access gap was family 
structure (26%) (Waidmann & Rajan, 2000). In summary, these studies demonstrated health 
insurance accounted for a sizable share of racial and ethnic disparities in access to a usual source 
of care (Lillie-Blanton & Hoffman, 2005).  
Of the eight comparisons in this review, health insurance explained a statistically 
significant share of the access gap in all four comparisons between Hispanics and whites and in 
three of the four comparisons between African Americans and whites (Lillie-Blanton & 
Hoffman, 2005). The one study that deviated from these otherwise consistent findings is the 
Weinick et al. (2000) study which differed in the way it structured its statistical analyses. In that 
study, the regression analysis included an interaction term for racial and ethnic characteristics 
and insurance status to separate the effect of racial and ethnic differences in health insurance on 
access to care (Lillie-Blanton & Hoffman, 2005). In order to examine how differences in 
insurance status and income might play a role in explaining racial and ethnic disparities, the 
researchers estimated linear probability models with an interaction term between 1) race and 
ethnicity and health insurance and 2) race and ethnicity and family income. They then used the 
regression estimates to simulate how much of the disparities between Hispanic and whites and 
between blacks and whites would change if Hispanics and blacks had health insurance coverage 
and income that was equivalent to that of whites (Weinick et al., 2000). The researchers found 
that changing the insurance coverage of blacks to be equivalent to that of whites had no 
statistically significant impact on the black-white disparity for usual source of care. 





reduction was seen in the Hispanic-white disparity for usual source of care. Changing the income 
of blacks and Hispanics to be equivalent to that of whites resulted in a 41% reduction in the 
black-white disparity and 21% reduction and the Hispanic-white disparity in usual source of care 
(Weinick et al., 2000). 
The remaining three studies utilized a regression decomposition method that allowed 
them to decompose the percentages of the total disparity that is associated with differences in the 
independent variables of interest. For instance, if the researcher were interested in determining 
how much of the total disparity was attributed to racial and ethnic differences in income, the 
researcher could simulate the outcome among one racial and ethnic group if that group had the 
income distribution of another racial and ethnic group while holding all other characteristics the 
same.  
The Affordable Care Act 
Provisions and Mandates 
The Patient Protection and Affordable Care Act, often shortened to the Affordable Care 
Act (ACA), was signed into law by President Barack Obama on March 23, 2010. The ACA 
attempted to achieve comprehensive health reform by improving health care access, quality, and 
cost control (McDonough, 2014; Sealy-Jefferson et al., 2015). The ACA includes numerous 
components intended to reduce health disparities, improve the quality of care, and address health 
insurance reform among racially and ethnically diverse populations (Andrulis et al., 2010).  
Several provisions of the ACA can be expected to have a positive impact on racial and 
ethnic minorities. Federal or state government-sponsored health insurance marketplace 
exchanges were established to provide private health insurance for individuals who are not 





requirements and who do not have access to employer-sponsored health insurance (McDonough, 
2014). Premium tax credits are available to individuals with incomes between 100-400% of the 
FPL who purchase health insurance through the marketplace exchange (Frean et al., 2017). 
Additionally, cost-sharing subsidies are available to eligible individuals to help reduce the 
portion of a claim that the insured will have to pay (KFF, 2012). The ACA health insurance 
marketplace exchanges commenced operation in every state on October 1, 2013, and by April 
2014, more than 8 million Americans purchased coverage through the ACA health insurance 
marketplace (ASPE, 2014).  
Another concrete action expected to affect racial and ethnically diverse people include 
employer-based health insurance reforms. In 2005, 71 percent of working-age whites had health 
insurance through their workplace, whereas only one-third of working-age Hispanics and half of 
working-age African Americans had employer-sponsored coverage (Doty & Holmgren, 2006). 
With ACA implementation, employers with ≥200 employees are mandated to automatically 
enroll employees into their health insurance plans, and employers with ≥50 employees must offer 
coverage to employees or pay a penalty for full-time employees that receive a tax credit for 
purchasing insurance through the exchanges (Andrulis et al., 2010; French et al., 2016; KFF, 
2012). Small employers with fewer than 25 full-time employees with average annual wages of 
less than $50,000 qualify for employer tax credits (H.R. 3590, 2010). Given that over 90% of 
minority-owned firms are small employers (≤25 employees), and diverse populations are more 
likely to be employed by small firms, the employer mandate has the potential to expand coverage 
for a sizeable amount of racially and ethnically diverse people (Lowrey, 2007).  
Low-income racially and ethnically diverse populations are expected to benefit the most 





insurance for many, though not all, low-income Americans (McDonough, 2014). The types of 
services offered vary by state; however, states are required by federal law to provide certain 
mandatory benefits. Some of these mandatory benefits include early and periodic health 
screening, diagnostic, and treatment services, inpatient and outpatient hospital services, 
physician services, laboratory and X-ray services, family planning services, transportation to 
medical care, nursing facility services, Certified Pediatric and Family Nurse Practitioner 
services, and home health services  Optional benefits that states may provide include prescription 
drugs, prosthetics, eye glasses, physical therapy, occupational therapy, podiatry, optometry, 
chiropractic, and dental services (Centers for Medicare & Medicaid Services, n.d.). 
Prior to ACA implementation, Medicaid income eligibility limits varied by state with 
some states (i.e., Alabama and Texas) setting their income eligibility for Medicaid well below 
20% of FPL. As implemented in January 2014, ACA Medicaid expansion extended coverage to 
individuals living at or below 138% of the FPL (Sealy-Jefferson, 2015). However, because of the 
Supreme Court’s ruling in the National Federation of Independent Business v. Sebelius case, 
states have the choice to opt out of implementation, so expansion is not consistent throughout the 
U.S. (Rosenbaum & Westmoreland, 2012). As of September 2019, 36 states and the District of 
Columbia have adopted Medicaid expansion, whereas 14 states have not (KFF, 2019b). For 
states that did not adopt Medicaid expansion, individuals whose incomes are above the Medicaid 
eligibility boundary for that state but below the lower limit to receive premium tax credits for 
marketplace insurance likely fall into the “coverage gap” and can remain uninsured 
(McDonough, 2014).  
Along with expanding both public and private insurance coverages, the ACA also 





requires most Americans without employer-sponsored health insurance to obtain health 
insurance or pay a penalty; however, Congress reduced the individual mandate penalty to $0 
effective in 2019 (Kamal et al., 2018). Young adults can remain under their parents’ health 
insurance until the age of 26 (dependent coverage provision). Insurance companies can no longer 
deny coverage to individuals based on health status or pre-existing conditions and can no longer 
charge more based on gender or health status (KFF, 2012). Insurers must provide comprehensive 
health plans that cover essential health benefits which include items and services in the following 
ten benefit categories: 1) ambulatory patient services; 2) emergency services; 3) hospitalization; 
4) maternity and newborn care; 5) mental health services and substance use disorder services; 6) 
prescription drugs; 7) rehabilitative services and devices; 8) laboratory services; 9) preventive 
services (i.e., screenings), wellness services, and chronic disease treatment; and 10) pediatric 
services (Centers for Medicare & Medicaid Services, n.d.). Lastly, the ACA prohibits insurers 
from imposing lifetime limits on coverage and prohibits them from rescinding coverage, except 
in cases of fraud (KFF, 2012). Through its various provisions, the ACA intends to make 
insurance options available to individuals who may not have been able to afford insurance or had 
access to employer-sponsored insurance prior to its implementation. 
The ACA and Insurance Coverage by Race and Ethnicity 
Analysis of data from the 2013 to 2016 American Community Survey (ACS) found that 
since ACA implementation, the proportion of uninsured Americans aged 0 to 64 fell from 17.0 
percent to 10.0 percent, meaning 18.5 million more Americans gained health insurance coverage 
(Skopec et al., 2018). Of this 18.5 million people, 10.9 million people had Medicaid coverage 
and 6.3 million people had private non-group coverage (Skopec et al., 2018). Although both 





expanded Medicaid saw a larger reduction in uninsured rates under the ACA. Between 2013 to 
2016, the uninsured rate fell by more than 50 percent in Medicaid expansion states with an 
additional 12.6 million people gaining coverage of which 9.7 million gained Medicaid coverage 
(Skopec, et al., 2018). In non-expansions states, the uninsured rate had a 31 percent decline, 
largely due to gains in private non-group coverage and employer-sponsored insurance (Skopec, 
et al., 2018). In 2016, uninsured rates for all racial and ethnic groups significantly fell and racial 
and ethnic gaps in uninsured rates narrowed. The uninsured rate fell by 8.2, 10.8, and 8.4 
percentage points for non-Hispanic blacks, Hispanics, and other or multiple races, respectively, 
compared to 5.7 percentage points for non-Hispanic whites (Skopec et al., 2018).  
In population-based studies of adults aged 18-64 years, Buchmueller et al. (2016), Chen 
et al. (2016), and McMorrow et al. (2015) found the percentage of uninsured adults significantly 
decreased for all racial and ethnic groups after implementation of the most significant pieces of 
the ACA such as young adult coverage (e.g., adults may remain on a parent’s insurance until the 
age of 26 year), marketplace exchanges, and Medicaid expansion; however, there was a larger 
decrease for blacks and Hispanics compared to whites (Buchmueller et al., 2016; Chen et al., 
2016). Additionally, there was a significant reduction in both the white-black and white-Hispanic 
coverage gaps after the 2014 ACA policy implementation (Buchmueller et al., 2016; McMorrow 
et al., 2015).  
McMorrow et al. (2015) utilized data from the National Health Interview Survey (NHIS) 
to examine changes in insurance coverage disparity gap among blacks, whites, and Hispanics 
through December 2014. Measuring absolute disparity (e.g., the difference between percentage 
of uninsured white and either the percentage of uninsured blacks or percentage of uninsured 





Hispanics to the percentage of uninsured whites), the study found a significant reduction in both 
absolute and relative disparity for black adults and a significant reduction in absolute disparity 
for Hispanics (McMorrow et al., 2015). However, when stratifying by state expansion status, 
Hispanics experienced a significant increase in relative disparity in expansion states, whereas 
blacks experienced a significant decline in relative disparity in non-expansion states. The authors 
surmise that the decline in relative disparity for blacks in non-expansion states may be due to 
strong Marketplace enrollment and increased participation among those previously eligible for 
Medicaid and that the incline in relative disparity for Hispanics in expansion states likely reflects 
immigrants’ restricted access to Medicaid and subsidies for Marketplace coverage (McMorrow 
et al, 2015). In a complementary study, Buchmueller et al. (2016) investigated the changes in the 
source of coverage using data from the 2008-2014 ACS. Findings revealed both private and 
public insurance coverages increased more for blacks and Hispanics than for Whites between 
2013 and 2014, and coverage gains were greater in states that expanded Medicaid (Buchmueller 
et al., 2016).  
Additional studies of the ACA’s effects of the Medicaid expansion on racial and ethnic 
disparities in insurance coverage found mixed empirical results (Lee & Porell, 2018; Yue et al., 
2018). In a quasi-experimental study examining the low-income (<138% FPL) adult population 
using 2013-2015 BRFSS data, Medicaid expansion was associated with a significant increase in 
the coverage gap between whites and Hispanics (Yue et al., 2018). Additionally, in a quasi-
experimental study of 2011-2016 BRFSS data, Lee and Porell (2018) also saw a widening of the 
coverage gap between whites and Hispanics in expansion versus non-expansion states; however, 
this result was not statistically significant. Neither study saw a significant change in the coverage 





Both studies have also examined measures of access (e.g., having a usual source of care, 
having a personal doctor and being unable to see a doctor due to costs). Yue et al. (2018) found 
that Medicaid expansion was associated with an increase in having a personal doctor and a 
decrease in being unable to see a doctor due to costs for both non-Hispanic whites and non-
Hispanic blacks; however, Medicaid expansion was not associated with any improvement in 
access outcomes for Hispanics. In fact, for the measure of having a personal doctor, researchers 
found that the disparity gap between non-Hispanic whites and Hispanics widened in both 
expansion and non-expansion states after ACA implementation. Additionally, although not 
statistically significant, an increase was seen in the white-Hispanic disparity for the probability 
of being unable to see a doctor due to costs, while a reduction was seen in the black-white 
disparity for the same measure (Yue et al., 2018). Similarly, Lee and Porell (2018) did not find 
any statistically significant evidence that Medicaid expansion reduced racial and ethnic 
disparities in access to care.    
The ACA and Diabetic Retinopathy Screening 
Although there is a considerable amount of literature that has examined the impact of the 
ACA on various health services and health outcomes, few studies have focused on ACA and 
racial and ethnic disparities regarding diabetic retinopathy screening. Shi et al. (2016) aimed to 
examine potential changes in eye examination rates across different racial and ethnic groups in 
adults (aged 18-64 years) with diabetes following ACA implementation. Using data from the 
2011 MEPS, the researchers simulated respondent samples for years 2014-2017. Results 
revealed that eye examination rates were forecasted to increase for minorities; however, some 
racial and ethnic disparities in eye examinations would continue to persist (Shi et al., 2016). The 





prevalence, and other social cultural factors in the predicted years would be the same as in 2011 
(Shi et al., 2016). Furthermore, the study did not examine the ACA Medicaid expansion’s role in 
reducing racial and ethnic disparities. 
In a similar study examining data from MEPS, Monnette, et al. (2019) examined changes 
in eye examination rates amongst individuals with diabetes from 2014 to 2015. The study 
revealed that eye examination rates significantly increased for both minorities (i.e., respondents 
not self-identified as “non-Hispanic white”) and non-Hispanic whites but increased by a greater 
amount for minorities. Also, the racial and ethnic disparity between minorities and non-Hispanic 
whites was reduced from 2014 to 2015. Although the racial and ethnic disparity between 
minorities and non-Hispanic whites was significant in 2014, adjusted models revealed that it was 
no longer significant in 2015. Among this study’s limitations was that it only focused on the first 
two years after the ACA implementation. Like Shi’s et al. (2016) study, it did not examine the 
effects of the ACA Medicaid expansion on racial and ethnic disparities in eye examination rates 
among the U.S. adult diabetic population.  
The present study intends to extend the research done by Shi et al. (2016) and Monnette 
et al. (2019) by 1) examining three full years of data post-ACA implementation; 2) calculating 
both absolute and relative disparities for individual racial and ethnic groups and examining how 
they have changed over time; and 3) using difference-in-difference analyses to examine the 
impact of the ACA Medicaid expansion on racial and ethnic disparities in eye examination rates 
among the U.S. diabetes population. At the time of this writing, this study is the first to use three 
full years of post-ACA data to estimate the impact of the ACA on racial and ethnic disparities in 
eye examination rates in U.S. adults with diabetes and is the first to focus on the effects of the 











This chapter details the research design and methodology used in the study. The chapter is 
divided into sections that include an overview of the research design, data source, study 
population, measures, and statistical analyses. 
Research Design 
A trend analysis was used to examine changes in eye examination rates over time while 
adjusting for predisposing, enabling, and need factors. Effects of Medicaid expansion on eye 
screening rates were examined using a quasi-experimental research design employing a 
difference-in-difference (DiD) analysis, which is used to study causal relationships in public 
health settings where randomized controlled trials are infeasible or unethical (Wing et al., 2018). 
Prior studies have utilized this design to study the effects of ACA Medicaid expansion by 
comparing the changes in health outcomes between the expansion states (treatment group) and 
non-expansion states (control group), before and after the policy change (Wherry & Miller, 
2016; Yue et al., 2018). Using 2010-2014 National Health Interview Survey data (NHIS) data, 
Wherry & Miller (2016) performed a DiD analysis to examine changes in health-related 
outcomes (e.g., insurance coverage, physician visits, hospitalizations, diabetes diagnosis, usual 
source of care, hypertension, cholesterol) in individuals 19-64 years living below 138% of the 
federal poverty level (FPL) residing in expansion states compared to those residing in non-
expansion states. The study has found Medicaid expansion was associated with higher rates of 
health insurance coverage and increased utilization of some types of health care. A similar study 
of BRFSS data performed a DiD analysis to assess Medicaid expansion impact on access to 





with statistically significant gains in health insurance coverage, having personal doctors, and 
affordability (Yue et al., 2018). 
Data Source 
This study was deemed exempt from review by the investigator’s Institutional Review 
Board. We used data from the 2010-2017 Medical Expenditure Panel Survey (MEPS). It 
provides national and regional level estimates on health insurance coverage, the frequency of 
healthcare utilization, the costs of these services, and sources of payment for the U.S. civilian 
noninstitutionalized population (AHRQ, 2018b). MEPS also collects data on respondents’ health 
status, demographic and socio-economic characteristics, employment status, access to care, and 
comorbidities (AHRQ, 2018b). MEPS employs a panel design in which five rounds of interviews 
are collected over two full calendar years. As illustrated below, rounds one and two are 
conducted in year one. Round three begins in year one and is completed in year three. Rounds 
four and five are conducted in the subsequent year (Figure 3.1). The response rates for MEPS 
2010-2017 range from 44.2% to 56.3% (AHRQ, n.d., 2019a). 
 
Figure 3.1. Schematic of Panels/Rounds for 2016 Calendar Year. Adopted from AHRQ (2018a). 
The MEPS data consist of a subsample of households that participate in the National 
Health Interview Survey (NHIS) which is a nationally representative, cross-sectional household 





for Health Statistics (NCHS). With an annual response rate of approximately 70 percent, NHIS 
collects information throughout the year from the civilian, non-institutionalized population. 
NHIS contains information on household, family, and individual demographic characteristics, as 
well as income, health status and other healthcare related variables (CDC, 2019a).  
The NHIS sampling employs an area probability, stratified multistage design (Parsons et 
al., 2014). An area probability sample includes geographic areas that are sampled with known 
probability (Lavrakas, 2008). In other words, each element in the sampling frame has a known, 
nonzero probability of being chosen (Groves et al., 2009, p. 98). Probabilities can be unequal in 
that some special populations (e.g., minorities) may have higher chances of being selected than 
others. This ensures that there are enough individuals included in the group to prepare separate 
estimates for the specified group (Groves et al., 2009, p. 98). For the 2008-2015 NHIS, black, 
Hispanic, and Asian persons are oversampled with adults aged 65 or older having a higher 
chance of being selected than other adults in the family (Parsons et al, 2014; CDC, 2019a).  
The NHIS sampling frame encompasses housing units in place at the time of the 2000 
U.S. Census (2008-2015 NHIS) and 2010 U.S. Census (2016 NHIS) (Parsons et al, 2014; CDC, 
2019a). In the first stage of sampling, primary sampling units (PSUs) consisting of single 
counties or combined contiguous counties are selected from each state. PSUs are then stratified 
into Census-defined blocks based on the Census minority concentration status for implementing 
differential sampling rates (Parsons et al, 2014). Within each stratum secondary sampling units 
are formed consisting of clusters of an expected 8, 12, or 16 sample household units. From each 
housing unit, the interview process collects information on the family, sample child (if children 





The MEPS has the same features of the NHIS complex survey design; but unlike the 
NHIS, college dorms represent ineligible housing units for MEPS. Analysis using MEPS data 
can be undertaken using either the individual or the family as the unit of analysis as a MEPS 
household may contain one or more family units, each consisting of one or more individuals 
(AHRQ, 2018b). MEPS is sampled from the previous year’s NHIS responding households. For 
example, a full calendar year data file for 2016 will contain rounds 3-5 of Panel 20 (which uses 
the 2014 NHIS sampling frame) and rounds 1-3 of Panel 21 (which uses the 2015 NHIS 
sampling frame) (AHRQ, 2018a).  
The Diabetes Care Survey is a component of MEPS that is administered to participants 
who answer a “yes” response to the survey question, “was the person ever told by a doctor or 
health professional that he/she had diabetes”. The Diabetes Care Survey asks health related 
questions such as the number of times hemoglobin was checked, whether the person had feet, 
eyes, or blood pressure checked, and whether the person had an influenza vaccination. 
Additional questions assess whether the participant treats his/her diabetes with insulin, oral 
medications, or diet (AHRQ, 2018b).  
For reasons of confidentiality, AHRQ restricts the use of certain MEPS variables 
including fully specified International Classification of Diseases (ninth revision) codes, fully 
specified industry and occupation codes, state and county federal information processing 
standards codes, census tract and block group codes, and federal and state marginal tax rates 
(AHRQ, 2019b). This study used restricted-access state identifiers in MEPS, and after approval 
by AHRQ, was performed in a NCHS Research Data Center. The RDC provides access to 
restricted-use data for statistical purposes while protecting the confidentiality of survey 






Inclusion criteria consisted of individuals aged ≥18 years who were diagnosed with 
diabetes (n=21,612). Individuals who did not identify as non-Hispanic white, non-Hispanic 
black, or Hispanic were excluded (n=2,109). Individuals with missing data on eye examination 
(n=4,354), education (n=121), have usual source of care (n=118), insulin use (n=118), and 
duration of diabetes (n=412) were excluded from the study bringing the total analytic sample size 
to 14,380 observations. For Medicaid expansion analysis, the analyses were further restricted to 
individuals living below 138% of the FPL bring the analytic sample size to 4,790 observations. 
Measures 
Outcome Variable  
The outcome for both research questions was operationalized by a survey question on  
whether “the respondent reported having an eye exam in which the pupils were dilated in the 
survey year”.  
Main Independent Variables  
The main independent variable for the first research question was race and ethnicity 
which included the categories of non-Hispanic white, non-Hispanic black, and Hispanic. The 
main independent variable for the second research question was operationalized based on 
whether an individual had resided in a state that expanded Medicaid and was conditional on 
when the state expanded. The expansion variable was coded as one (expansion) if the survey 
respondent’s residential state implemented Medicaid expansion prior to the respondent’s MEPS 
interview date. For example, for the states that implemented Medicaid expansion January 1, 
2014, the treatment variable was coded as one if the interview occurred after this date. The 





implementation of Medicaid expansion or if the respondent had resided in a state that did not 
expand Medicaid expansion during the study period. During the time of our study period (2010-
2017), 31 states and the District of Columbia implemented Medicaid expansion and 19 states did 
not implement Medicaid expansion (Table 3.1).  
 
Table 3.1 
ACA Medicaid Expansion Date for Expansion States (KFF, 2019a) 
Expansion States (*n=32) 
State 
Date of ACA Medicaid 
expansion 
Arizona, Arkansas, California, Colorado, 
Connecticut, District of Columbia, Delaware, 
Hawaii, Illinois Iowa, Kentucky, Maryland, 
Massachusetts, New York, North Dakota Ohio, 
Oregon, Rhode Island, Vermont, Washington, West 
Virginia 
January 1, 2014 
Michigan April 1, 2014 
New Hampshire August 15, 2014 
Indiana February 1, 2015 
Alaska September 1, 2015 
Pennsylvania January 1, 2015 
Montana January 1, 2016 
Louisiana July 1, 2016 
Non-expansion States (n=19) 
Alabama, Florida, Georgia, Idaho, Kansas, Maine, Mississippi, Missouri, Nebraska, 
North Carolina, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, 
Virginia, Wisconsin, Wyoming 
Note. *Includes the District of Columbia  
 
Control Variables  
As previously described in the literature review section, categorization of the control 





included age, sex, marital status (married/ partnered or single/ never married/ widowed/ 
divorced/separated) and education (<12 years versus ≥12 years). Prior studies of individuals with 
diabetes have shown respondents who are older in age, female, married/partnered, and have a 
higher level of education are more likely to obtain eye examinations (Chen et al., 2014; 
Monnette et al., 2019; Shi et al., 2014). The enabling factors included economic status (living 
below 138% of FPL, living above 138% of FPL insurance status (insured, not insured), whether 
respondent has a usual source of care (yes/no), all which have been shown to be associated with 
receipt of eye care (Chen et al., 2014; Tran et al., 2017). Need factors included whether the 
individual takes insulin (yes/no) and duration of diabetes. As an indicator for diabetes severity, 
insulin use has been positively associated with eye examination use (Chen et al., 2014), and 
research has shown that duration of diabetes is positively associated with the diabetic retinopathy 
prevalence and thus, might influence eye examination utilization (ADA, 2019; Solomon et al., 
2017; Zhao et al., 2014). 
Statistical Analyses 
All analyses were completed using Stata (version 16; StataCorp, College Station, TX). 
The svyset command was used to establish the survey design for the dataset. The MEPS design 
variables (STRATA and PSU) were used to account for the complex survey design and 
nonresponse and appropriate weights were applied to produce national estimates. Statistical 
significance was determined at p<0.05.  
Trend Analyses (Research Question #1) 
The study population included individuals aged 18 years or older who responded yes to 
“having ever been diagnosed with diabetes.” Descriptive statistics of the study population were 





study population characteristics changed over time. In crude analyses, weighted proportions of 
eye examination were generated for each survey year overall and by race and ethnicity. For each 
survey year, a Pearson’s chi-squared test was performed to test differences in the proportion of 
eye examinations between each race and ethnicity group. Multivariable logistic regression 
models (controlling for the predisposing, enabling, and need factors) followed by the margins 
command were used to estimate adjusted prevalence of eye examinations and margins dydx was 
used to estimate marginal effects for each covariable.  
Medicaid Expansion Analyses (Research Question #2) 
 The study population included U.S. adults with diabetes living below 138% of the FPL. 
Baseline study population characteristics were calculated separately for expansion versus non-
expansion states for 2010 (base study year), 2014 (middle study year), and 2017 (last study year). 
A Pearson’s chi-squared test was used to evaluate differences in characteristics of individuals 
residing in expansion and non-expansion states. A difference-in-difference (DiD) analysis was 
employed to estimate the effects of the ACA Medicaid expansion on eye examination rates. Prior 
studies have utilized this design to study the effects of ACA Medicaid expansion by comparing 
the changes in outcomes between the expansion group (treatment group) and non-expansion 
group (control group), before and after the policy change (Lee & Porell, 2018; Yue et al, 2018). 
We estimated the following logistic regression model:  
  log[ist/1- ist ]=0 + 1Treatmentst + 2Xist + t + s  
where log[ist/1- ist ] is the outcome for individual i in state s with a survey date in year t. 
Treatmentst is a dummy variable equal to 1 for individuals residing in an expansion state at the 
time of the survey interview and 0 otherwise. t represents the year fixed effects, which control 





which control for state-specific time-invariant characteristics. Xist is a vector of individual 
characteristics of respondents that include predisposing, enabling, and need factors. The DiD 
estimator (1) captured the change in outcome among individuals in Medicaid expansion states 
relative to individuals in non-expansion states after the expansion.  
DiD relies on the assumption that pre-policy trends are similar in the treatment and 
control groups and any post-policy trends are attributable to the policy (Bertrand et al., 2003). 
This would hold true if changes in outcomes over time in each group differ by a fixed amount in 
every time period and exhibit a common set of period-specific changes (Wing et al., 2018). 
Therefore, any observed divergence between expansion and non-expansion states that occurs in 
post-policy years can be attributed to the impact of the ACA Medicaid expansions rather than a 
pre-existing differential trend (Wherry & Miller, 2016). When this assumption is violated, (e.g., 
when a change occurs in one group but not the other at the same time of the intervention), the 
resulting estimates will be biased. The following model was used to assess the parallel trend 
assumption: 
log[ist/1- ist ] =0 + 1Treatmentst  + 2TR + 3Treatmentst*TR + 4Xist  
where log[ist/1- ist ] is the outcome for individual i in state s with a survey date in year t. 
Treatmentst is a dummy variable equal to 1 for individuals residing in an expansion state at the 
time of the survey interview and 0 otherwise. TR is a linear time trend for the period ending in 
2013. Xist is a vector of individual characteristics of respondents that includes predisposing, 
enabling, and need factors. The estimate for the interaction term between treatment and trend 
was found to be nonsignificant at (odds ratio [OR]:0.99, 95% confidence interval [CI]:0.97-1.01, 
p=0.585) suggesting no significant difference in pre-expansion trends between expansion and 






 The chapter presents the results obtained from the data analysis. This study examined 
trends in eye examination rates among U.S. adults (aged≥18 years) with diabetes, assessed racial 
and ethnic differences in eye examination rates, and assessed changes in eye examination rates in 
individuals with diabetes living below 138% of the federal poverty level (FPL) in states that 
expanded Medicaid compared to those that did not using data from the 2010-2017 Medical 
Expenditure Panel Survey (MEPS). Sociodemographic and health-related characteristics are 
summarized in Table 4.1. 
Description of Study Population 
 Majority of adults were non-Hispanic white (67.2%), 45-64 years of age (45.1%), women 
(50.5%), had ≥12 years education (80.1%), were married or partnered (56.5%), were living at or 
above 138% of the FPL (77.2%), were insured (93.3%), had a regular provider (93.3%), were 
non-insulin users (69.2%), and reported having diabetes for greater than 10 years (43.7%). 
Throughout the study years, the distribution of all characteristics remained the same with the 
exception of insurance status (p for trend <0.001), having a usual provider (p for trend =0.046), 
and duration of diabetes (p for trend <0.001). There was an overall downward trend in the crude 
rate of uninsured adults from 8.9% in 2010 to 6.1% in 2014 (p =0.003) to 4.1% in 2017 
(p=0.019) (see Appendix A). The proportion of adults with a usual provider was not stable 
across years with the lowest percentages of 92.6% reported in 2012 and 92.5% reported in 2013 
and the highest percentages of 94.4% reported in 2011 and 94.5% reported in 2014 (see 
Appendix B). There was an overall downward trend in the percentage of adults who had a 
diabetes duration of 0-5 years from 36.8% in 2010 to 28.5% in 2017, and an upward trend in the 





50.2% in 2017. The percentage of adults with diabetes for 6-10 years remained relatively stable 






Characteristics of Adults with Diabetes in the U.S.: 2010-2017 MEPS 


















Total Sample 14380 1594 1762 1947 1820 1775 1807 1828 1847 
Eye Examination 8980 (65.5) 990 (65.7) 1103 (65.7) 1222 (66.6) 1107 (65.1) 1103 (65.3) 1143 (65.7) 1137 (65.2) 1175 (64.9) 
Race and Ethnicity          
NH-white 6420 (67.2) 777 (69.0) 835 (67.1) 810 (66.7) 747 (68.0) 745 (67.8) 772 (65.9) 804 (66.8) 930 (66.5) 
NH-black 3866 (16.3) 416 (16.1) 486 (16.9) 550 (16.2) 525 (16.1) 509 (16.0) 494 (16.9) 460 (15.9) 426 (16.5) 
Hispanic 4094 (16.5) 401 (14.8) 441 (16.0) 587 (17.1) 548 (15.9) 521 (16.2) 541 (17.2) 564 (17.2) 491 (17.0) 
Age Group          
18 to 44 years 1948 (11.8) 239 (13.8) 270 (14.1) 280 (12.0) 249 (11.0) 238 (10.9) 233 (10.9) 235 (11.3) 204 (10.8) 
45 to 64 years 6724 (45.1) 770 (47.2) 830 (47.4) 903 (44.7) 867 (44.3) 814 (43.1) 853 (45.3) 867 (45.2) 820 (44.1) 
>=65 years 5708 (43.1) 585 (38.0) 662 (38.5) 764 (43.3) 704 (44.7) 723 (46.0) 721 (43.8) 726 (43.6) 823 (45.2) 
Sex          
Men 6475 (49.5) 696 (49.3) 788 (50.8) 907 (50.8) 838 (50.0) 761 (46.9) 800 (48.4) 829 (49.3) 856 (50.9) 
Women 7905 (50.5) 898 (50.7) 974 (49.2) 1040 (49.2) 982 (50.0) 1014 (53.1) 1007 (51.6) 999 (50.7) 991 (49.1) 
Education          
<12 years 4090 (19.9) 475 (21.5) 541 (21.5) 554 (20.9) 557 (20.6) 481 (17.9) 490 (18.2) 516 (19.3) 476 (19.7) 
≥12 years 10390 (80.1) 1119 (78.5) 1221 (78.5) 1393 (79.1) 1263 (79.4) 1294 (82.1) 1317 (81.8) 1312 (80.7) 1371 (80.3) 
Marital Status          
Married/partnered 7528 (56.5) 832 (57.3) 882 (56.0) 997 (56.6) 933 (56.3) 877 (56.4) 937 (59.3) 907 (56.8) 893 (53.0) 
Single 7122 (43.5) 762 (42.7) 880 (44.0) 950 (43.4) 887 (43.7) 898 (43.6) 870 (40.7) 921 (43.2) 954 (47.0) 
Economic Status          
<138% FPL 4794 (22.8) 524 (23.8) 586 (22.6) 677 (23.8) 616 (22.7) 632 (25.3) 586 (21.2) 601 (21.5) 575 (22.1) 
≥138% FPL 9583 (77.2) 1070 (76.2) 1176 (77.4) 1270 (76.2) 1204 (77.3) 1143 (74.7) 1221 (78.8) 1227 (78.5) 1272 (77.9) 
*Insured          
Uninsured 1289 (6.7) 187 (8.9) 212 (8.4) 238 (8.2) 209 (8.2) 167 (6.1) 135 (5.0) 143 (5.3) 98 (4.1) 
Insured   12991 (93.3) 1407 (91.1) 1550 (91.6) 1709 (91.8) 1611 (91.8) 1608 (93.9) 1672 (95.0) 1685 (94.7) 1749 (95.9) 
*Has Usual Provider          
Yes 13234 (93.3) 1470 (93.3) 1626 (94.4) 1763 (92.6) 1660 (92.5) 1660 (94.9) 1670 (93.4) 1677 (92.7) 1708 (92.8) 
No 1146 (6.7) 124 (6.7) 136 (5.6) 184 (7.4) 160 (7.5) 115 (5.1) 137 (6.6) 151 (7.3) 139 (7.2) 
Takes Insulin          
Yes 4570 (30.8) 493 (30.7) 571 (32.5) 651 (32.1) 589 (30.5) 554 (30.5) 549 (29.9) 578 (30.3) 585 (30.3) 
No 9810 (69.2) 1101 (69.3) 1191 (67.5) 1296 (67.9) 1231 (69.5) 1221 (69.5) 1258 (70.1) 1250 (69.7) 1262 (69.7) 
*Diabetes Duration          
0-5 years 4851 (33.5) 573 (36.8) 644 (35.8) 695 (35.2) 642 (35.4) 598 (34.1) 593 (33.1) 568 (30.4) 538 (28.5) 
6-10 years 3257 (22.8) 391 (24.9) 399 (22.4) 443 (22.7) 420 (23.7) 402 (22.8) 389 (21.2) 418 (23.4) 395 (21.4) 
>10 years 6272 (43.7) 630 (38.3) 719 (41.8) 809 (42.1) 758 (40.9) 775 (43.1) 825 (45.6) 842 (46.2) 914 (50.2) 





Crude Trends and Racial and Ethnic Differences in Eye Examination Rates 
 Across 2010-2017, there were no significant changes in the overall study population’s 
crude eye examination rates of (p for trend=0.995) (Figure 4.1). Throughout the 8-year study 
period, on average 65.5% (95% CI: 64.3-66.7) of U.S. adults with diabetes received an eye 
examination (Table 4.1). In 2010, the overall study population’s crude eye examination rate was 
65.7% (95% CI: 62.9-68.5) which did not significantly differ from the 2014 (middle study year) 
rate (65.3%, 95% CI: 62.2-68.3, p=0.084) or from the 2017 rate (64.9%, 95% CI: 62.1-67.5, 
p=0.667). Similarly, no significant trends were noted among non-Hispanic whites, non-Hispanic 
blacks, and Hispanics (p for trend=0.984, 0.674, and 0.419, respectively) (Figure 4.1).  
Figure 4.1 
 
Figure 4.1. Crude trends in eye examination rates among U.S. adults (age ≥18 years) with 





 In examining differences in crude eye examination rates by race and ethnicity, there were 
statistically significant differences in the average crude eye examination rates for Hispanics 
compared to non-Hispanic whites (58.0%, 95% CI: 55.7-60.2 vs  67.8%, 95% CI: 66.2-69.5, 
p<0.001); non-Hispanic blacks compared to non-Hispanic whites (63.4%, 95% CI: 61.4-65.5 vs 
67.8%, 95% CI: 66.2-69.5, p<0.001); and Hispanics compared to non-Hispanic blacks (58.0%, 
95% CI: 55.7-60.2 vs 63.4%, 95% CI: 61.4-65.5, p<0.001). Except for 2014, a significant 
difference in eye examination rates persisted between non-Hispanic whites and Hispanics 
throughout the study period (Figure 4.1).  
Adjusted Trends and Racial and Ethnic Differences in Eye Examination Rates 
 Multivariable logistic regression models were used to assess trends and examine racial 
and ethnic differences in eye examination rates while controlling for year and state fixed effects, 
predisposing factors, enabling factors, and need factors (Table 4.2). When controlling for the 
predisposing factors (i.e., age, sex, education, marital status), the average adjusted rates for eye 
examination for the overall population did not significantly change throughout the study period 
(66.5%, 95% CI: 63.9-69.1 for 2010 vs 65.0%, 95% CI: 62.0-67.3 for 2017) (p for trend=0.913). 
The average adjusted rate of eye examination for Hispanics was 2.9 percentage points lower than 
that of non-Hispanic whites (65.9%, 95% CI: 64.3-67.7, p=0.047). For each study year, the 
adjusted rate of eye examination for Hispanics was significantly lower than that of non-Hispanic 
whites. No significant differences were seen in adjusted eye examination rates between non-
Hispanic whites and non-Hispanic blacks for any of the study years (Figure 4.2a).  
 In the model adjusting for enabling factors (i.e., insurance status, have a usual provider, 
and economic status), the average adjusted rates for eye examination for the overall population 





vs 64.3, 95% CI: 61.5-66.9 for 2017) (p for trend=0.931). The average adjusted rate of eye 
examination for non-Hispanic whites was 2.7 percentage points and 4.7 percentage points higher 
than those of non-Hispanic blacks (64.0%, 95% CI: 62.1-65.9, p=0.029) and Hispanics (61.9%, 
95% CI: 59.6-64.3, p=<.001), respectively (Table 4.2). For each study year, the adjusted rate of 
eye examination for non-Hispanic whites was higher than that of non-Hispanic blacks and 
Hispanics (Figure 4.2b). 
 The average adjusted eye examination rates for the overall population in the model 
controlling for need factors (i.e., insulin use and duration of diabetes) did not significantly 
change throughout the study period (66.2%, 95% CI: 63.5-68.9 for 2010 vs 64.0, 95% CI: 61.4-
66.7 for 2017) (p for trend=0.939). For combined study years, the average adjusted rate of eye 
examination significantly differed among the races and ethnicities. The average adjusted eye 
examination rates for non-Hispanic whites was 4.5 percentage points and 9.5 percentage points 
higher than those of non-Hispanic blacks (63.3%, 95% CI: 61.3-65.4, p<.001) and Hispanics 
(58.2%, 95% CI: 56.1-60.5, p<.001), respectively (Table 4.2). For each study year, the adjusted 
rate of eye examination for non-Hispanic whites was higher than that of non-Hispanic blacks and 
Hispanics (Figure 4.2c).  
 In the model controlling for all predisposing, enabling, and need factors, although a 
downward trend was seen in eye examination rates, the average adjusted eye examination rates 
for the overall population did not significantly change throughout the study period (67.3%, 95% 
CI: 64.8-69.8 for 2010 vs 63.8, 95% CI: 61.2-66.5 for 2017) (p for trend=0.562) (see Appendix 
D). Adjusting for all factors eliminated any previous significant differences seen in eye 
examination rates between non-Hispanic whites and non-Hispanic blacks and non-Hispanic 





 Additional fully adjusted models were estimated to assess interactions between race and 
ethnicity and insurance status, as well as race and ethnicity and income. Analyses revealed that 
there was a different relationship between race and ethnicity and receipt of eye examination for 
those who are insured compared to those who are not insured. The difference in eye examination 
rates between insured compared to uninsured was significantly higher for non-Hispanic whites 
(67.0%, 95% CI: 65.4-68.6 vs 44.4%, 95% CI: 38.1-50.6, p<.001), followed by non-Hispanic 
blacks (66.7%, 95% CI: 64.8-68.7 vs 50.6%, 95% CI: 44.0-57.1, p<.001), and Hispanics (65.6%, 
95% CI: 63.1-68.0 vs 53.0%, 95% CI: 48.0-58.0, p<.001) (see Appendix E). When assessing the 
interaction between race and ethnicity and income, the difference in eye examination rate 
between those with incomes ≥138% FPL compared to those with incomes <138% FPL was 
significantly higher for non-Hispanic whites (66.8%, 95% CI: 65.1-68.5 vs 61.1%, 95% CI: 58.4-
63.8, p<0.001); no significant differences were seen in non-Hispanic blacks or Hispanics (see 
Appendix F).  
A likelihood ratio test was used to evaluate differences between the predisposing, 
enabling, need, and full models to identify the model which fit the data the best. Based on the 
results of the likelihood ratio test, the full model had the better fit compared to each of the 
smaller models (models with predisposing, enabling, and need factors; each p<0.001) (see 
Appendix G). 








Adjusted Prevalence of Eye Examination Among U.S. Adults with Diabetes: 2010-2017 MEPS 
 Model with Predisposing Factors Model with Enabling Factors Model with Need Factors Full Model 
 AAP, % 95% CI P-value AAP, % 95% CI P-value AAP, % 95% CI P-value AAP, % 95% CI P-value 
Year              
2010 66.5 63.9-69.1 ref. 66.2 63.7-68.9 ref. 66.2 63.5-68.9 ref. 67.3 64.8-69.8 ref. 
2011 66.7 64.1-69.4 0.889 65.8 63.1-68.6 0.830 65.9 63.2-68.5 0.853 66.8 64.2-69.4 0.751 
2012 66.7 63.8-69.5 0.937 67.1 64.2-70.0 0.629 66.8 63.9-69.7 0.752 67.2 64.4-69.9 0.937 
2013 64.8 62.1-67.5 0.375 65.5 62.9-68.3 0.721 65.4 62.7-68.1 0.663 65.6 63.0-68.2 0.351 
2014 64.5 61.5-67.5 0.324 65.0 62.2-67.9 0.555 65.4 62.5-68.4 0.684 64.6 61.7-67.4 0.170 
2015 65.1 62.4-67.6 0.440 65.1 62.5-67.6 0.569 65.6 63.1-68.2 0.771 64.8 62.3-67.2 0.152 
2016 65.0 62.2-67.7 0.429 65.9 62.1-67.6 0.495 64.8 61.9-67.5 0.471 64.6 61.8-67.3 0.152 
2017 65.0 62.0-67.3 0.340 64.3 61.5-66.9 0.307 64.0 61.4-66.7 0.259 63.8 61.2-66.5 0.059 
Race and Ethnicity              
NH-White 65.9 64.3-67.6 ref. 66.7 64.1-68.2 ref. 67.7 66.2-69.4 ref. 65.6 64.1-67.1 ref. 
NH-Black 65.8 63.8-67.7 0.880 64.0 62.1-65.9 0.029 63.3 61.3-65.4 <.001 65.6 63.7-67.5 0.960 
Hispanic 63.1 60.9-65.4 0.047 61.9 59.6-64.3 <.001 58.2 56.1-60.5 <.001 65.1 62.8-67.3 0.734 
Age              
18 to 44 years 49.6 46.2-52.8 ref.       53.5 50.1-56.7 ref. 
45 to 64 years 60.5 58.8-62.1 <.001       62.1 60.5-63.4 <.001 
>=65 years 74.7 73.1-76.3 <.001       72.4 70.1-74.0 <.001 
Sex              
Men 64.5 62.9-66.1 ref.       64.7 63.266.1 ref. 
Women 66.3 64.7-67.8 0.082       66.3 64.8-67.8 0.094 
Education              
<12 years 56.3 54.0-58.5 ref.       57.6 55.4-59.9 ref. 
≥12 years 67.8 66.5-69.1 <.001       67.5 66.2-68.7 <.001 
Marital Status              
Single 61.4 59.8-63.1 ref.       61.9 60.3-63.6 ref. 
Married/partnered 68.6 67.1-70.0 <.001       68.3 66.8-69.6 <.001 
Economic status             
<138% FPL    60.8 58.8-62.8 ref.    62.9 61.1-64.8 ref. 
≥138% FPL    66.8 65.5-68.2 <.001    66.2 65.1-67.5 0.002 
Has Usual Provider              
No    50.3 46.1-54.5 ref.    54.5 50.5-58.6 ref. 
Yes    66.5 65.3-67.7 <.001    66.3 65.2-67.4 <.001 
             
             





 Model with Predisposing Factors Model with Enabling Factors Model with Need Factors Full Model 
 AAP, % 95% CI P-value AAP, % 95% CI P-value AAP, % 95% CI P-value AAP, % 95% CI P-value 
Insurance Status             
Uninsured    42.2 38.4-45.8 ref.    48.9 45.0-52.7 ref. 
Insured      67.1 65.9-68.4 <.001    66.7 65.5-67.9 <.001 
Takes insulin              
No       63.5 62.2-65.1 ref. 62.9 70.0-73.2 ref. 
Yes       70.0 68.2-71.7 <.001 71.6 61.5-64.3 <.001 
Diabetes Duration              
0-5 years       55.8 53.7-57.7 ref. 58.8 56.8-60.7 ref. 
6-10 years       67.4 64.9-69.7 <.001 67.3 65.0-69.6 <.001 
>10 years 66.5 63.9-69.1 ref. 66.2 63.7-68.9 ref. 72.1 70.6-73.7 <.001 70.0 68.5-71.6 <.001 
Note. Reference groups are year=2010, race/ethnicity=NH-whites, age=18-44 years, men, education= ≤12 years, marital status=single, economic status=<138% FPL, usual 
provider=no, insurance status=uninsured, insulin use=no, and duration of diabetes=0-5 years. Bold font indicates statistical significance at P<0.05. AAP, average adjusted 




















Figure 4.2. Adjusted trends in eye examination rates among U.S. adults (age ≥18 years) with diabetes: MEPS 2010-2017. Error bars 








Medicaid Expansion Analyses 
 For Medicaid Expansion analysis, we restricted our study population to adults with 
diabetes living below 138% of the FPL. The aforementioned adjusted analysis demonstrated a 
significant difference in eye examination rates between adults living at or above 138% of the 
FPL compared to adults living below 138% of the FPL. The former had 3.3 percentage points 
(95% CI: 1.2-5.4) higher eye examination rates compared to the latter (p=0.002) (Table 4.2).  
 The characteristics of U.S. adults with diabetes living below 138% of the FPL are 
summarized for 2010 (base study year), 2014 (middle study year), and 2017 (last study year) by 
expansion status (Table 4.3). In 2010, the distribution of all characteristics did not significantly 
differ between individuals residing in never-expanding states and states that expanded Medicaid 
later on. With the exception of insurance status, no significant differences were observed for 
2014 and 2017. Fewer individuals residing in expansion states reported being uninsured 
compared to individuals residing in non-expansion states in 2014 (5.4% vs 15.1%, p=0.001) and 
in 2017 (2.6% vs 11.0%, p<0.001). By the end of 2014, 26 states and the District of Columbia 
expanded Medicaid representing 45.7% of the study population, and as of the end of 2017, 31 
states and the District of Columbia expanded Medicaid representing 52.4% of the study 







Characteristics of Adults with Diabetes Living below 138 % of the Federal Poverty Level, by Medicaid Expansion Status 
















expansion   
n (%) 
P-value 
Eye examination 167 (62.2) 140 (57.1) 0.310 185 (56.2) 186 (62.1) 0.249 182 (61.4) 151 (52.2) 0.071 
Race/ethnicity   0.571   0.261   0.022 
NH-white 106 (55.0) 75 (50.4)  97 (55.4) 85 (52.9)  125 (53.8) 89 (49.4)  
NH-black 69 (17.8) 90 (23.4)  87 (16.6) 128 (25.1)  64 (20.1) 111 (32.7)  
Hispanic 110 (27.3) 74 (26.2)  148 (27.9) 87 (22.0)  105 (25.1) 81 (18.0)  
Age group   0.344   0.057   0.651 
18 to 44 years 47 (14.0) 47 (19.8)  71 (16.9) 36 (8.2)  45 (15.6) 29 (14.0)  
45 to 64 years 133 (47.4) 113 (47.0)  140 (42.4) 138 (43.9)  125 (40.8) 126 (45.7)  
>=65 years 105 (38.6) 79 (33.2)  121 (40.7) 126 (47.8)  124 (43.6) 126 (40.3)  
Sex   0.308   0.491   0.085 
Men 99 (38.5) 72 (33.8)  111 (38.2) 108 (35.2)  107 (40.7) 86 (32.1)  
Women 186 (61.5) 167 (66.2)  413 (63.1) 192 (64.8)  187 (59.3) 195 (67.9)  
Education   0.103   0.254   0.295 
<12 years 131 (37.7) 127 (37.7)  181 (61.0) 179 (66.3)  183 (66.6) 170 (71.7)  
≥12 years 154 (62.3) 112 (51.9)  151 (39) 121 (33.7)  111 (33.4) 111 (28.2)  
Marital Status   0.412   0.603   0.745 
Married/partnered 100 (31.9) 80 (36.6)  110 (37.0) 100 (33.9)  80 (28.1) 75 (26.6)  
Single 185 (68.1) 159 (63.4)  222 (63.1) 200 (66.1)  214 (71.9) 206 (73.4)  
Insurance Status   0.129   0.001   <.001 
Uninsured 45 (11.8) 44 (17.0)  31 (5.4) 51 (15.1)  10 (2.6) 29 (11.0)  
Insured 240 (88.2) 195 (83.0)  301 (94.6) 249 (84.9)  284 (97.5) 252 (88.9)  
Has regular provider   0.441   0.587   0.109 
Yes 257 (91.2) 218 (92.9)  305 (93.2) 280 (94.5)  272 (93.4) 254 (88.9)  
No 28 (8.7) 21 (7.1)  27 (6.8) 20 (5.5)  22 (6.6) 27 (11.1)  
Takes insulin   0.975   0.090   0.249 
Yes 94 (33.5) 84 (33.4)  118 (40.7) 110 (32.3)  96 (32.3) 107 (37.6)  
No 191 (66.4) 155 (66.6)  214 (59.3) 190 (67.7)  198 (67.7) 174 (62.4)  
          
    
    


























  0.713   0.559   0.572 
0-5 years 97 (34.5) 86 (36.8)  112 (33.7) 98 (30.6)  86 (25.2) 80 (27.9)  
6-10 years 73 (34.7) 63 (26.8)  68 (21.9) 72 (26.4)  60 (21.2) 52 (17.3)  
>10 years 115 (40.9) 90 (36.4)  152 (44.4) 130 (43.0)  148 (53.6) 149 (54.8)  
*Expansion status, # 
states (% of population) 
0 (0.0) 51 (100.0)   27 (45.7) 24 (54.3)   32 (52.4) 19 (47.6)   







 Five multivariable logistic regression models were used to estimate treatment effects. The 
first model (and each subsequent model) included the treatment dummy variable and controlled 
for state and year fixed effects. The second, third, and fourth models were adjusted for 
predisposing, enabling, and need factors, respectively, and the fifth model was adjusted for all 
factors.  
 Based on the results of the first model, the adjusted prevalence of eye examination rates 
among the study population residing in states that expanded Medicaid was 2.4 percentage points 
lower than the rate of those residing in states that did not expand; however, this difference was 
not statistically significant (p=0.547) (Table 4.4). Similar nonsignificant results were seen for the 
second (predisposing), third (enabling), and fourth (need) models in that the study population 
residing in the states that expanded had a lower adjusted prevalence of examinations than those 
residing in the states that did not expand (model 2: -2.1 percentage points change, p=0.571; 
model 3: -2.5 percentage points change, p=0.513; and model 4: -3.2, p=0.399). The fully 
adjusted model also did not find any statistically significant differences in the adjusted 
prevalence of eye examination rates in states that expanded versus states that did not expand 
Medicaid (59.4, 95% CI: 56.8-62.1 vs 56.4, 95% CI: 50.9-62.0, p=0.413) (Table 4.4). Further, no 
significant interaction was seen between expansion status and race and ethnicity which suggests 
that changes in eye examination rates did not significantly differ in expansion versus non-
expansion states for non-Hispanic whites (-6.0 percentage points change, p=0.210), non-Hispanic 
blacks (1.6 percentage points change, p=0781) and Hispanics (-2.0 percentage points change, 
p=0.698). 
A likelihood ratio test was used to evaluate differences between the predisposing, 





results of the likelihood ratio test, the full model had the better fit compared to each of the 
smaller models (models with predisposing, enabling, and need factors; each p<0.001) (see 
Appendix G). 
Sensitivity analyses were performed to examine whether changes in eye examination 
rates differed by level of exposure to Medicaid expansion. Three different treatment variables 
were used in fully adjusted models: 1) years since expansion modeled as a continuous variable, 
2) treatment with a 1-year post-expansion lag, and 3) treatment with a 2-year post-expansion lag. 
We did not find any significant changes in eye examination rates for any of the treatment 
variables (model 1-OR:1.1, 95% CI: 0.9-1.2, P=0.346; model 2-OR:1.1,  95% CI: 0.8-1.6, 








Changes in Eye Examination Rates among Diabetic Respondents Living below 138% of the Federal Poverty Line,  Before and After Medicaid Expansion 
 Model 1 Model 2 Model 3 Model 4 Model 5 
 
AAP 95% CI 
P-
value AAP 95% CI 
P-
value AAP 95% CI 
P-
value AAP 95% CI 
P-
value AAP 95% CI 
P-
value 
Treatment Effects                
Non-Expansion 59.3 56.4-62.1 ref. 59.2 56.4-61.9 ref. 59.3 56.5-62.1 ref. 59.5 56.7-62.2 ref. 59.4 56.8-62.1 ref. 
Expansion 56.8 50.9-62.7 0.547 57.1 51.4-62.7 0.572 56.8 51.0-62.5 0.513 56.3 50.5-62.0 0.399 56.4 50.9-62.0 0.413 
Race and ethnicity                 
NH white    57.9 54.9-60.8 ref.       57.5 54.7-60.2 ref. 
NH black    59.9 56.5-63.3 0.397       59.2 55.7-62.6 0.477 
Hispanic    58.9 55.2-62.7 0.666       60.4 56.6-64.2 0.242 
Age                 
18 to 44 years    44.5 40.1-49.1 ref.       49.2 44.4-53.9 ref. 
45 to 64 years    53.8 51.2-56.4 <.001       55.4 52.8-58.0 <.001 
>=65 years    69.6 66.8-72.4 <.001       55.1 63.2-69.0 <.001 
Sex                 
Men    56.3 53.4-59.2 ref.       57.1 54.2-59.8 ref. 
Women    60.1 57.8-62.4 0.036       59.6 57.4-61.7 0.138 
Education                 
<12 years    54.3 51.3-57.2 ref.       54.6 51.6-57.4 ref. 
≥12 years    61.2 58.9-63.4 <.001       61.1 58.9-63.1 <.001 
Marital Status                 
Married/partnered    61.1 58.1-64.1 ref.       61.7 58.7-64.6 ref. 
Single    57.3 54.9-59.7 0.058       57.1 54.8-59.4 0.017 
Has Usual Provider                 
No       43.3 37.3-49.3 ref.    47.6 41.4-53.8 ref. 
Yes       60.2 58.2-62.1 <.001    59.7 57.9-61.7 <.001 
Insurance Status                
Uninsured       38.8 33.4-44.1 ref.    44.7 39.1-50.3 ref. 
Insured         61.1 59.1-63.2 <.001    60.4 58.4-62.5 <.001 
Takes Insulin                 
No          56.8 54.4-59.2 ref. 56.2 54.1-58.4 ref. 
Yes          61.9 58.9-64.9 0.008 62.9 60.0-65.8 <.001 
Diabetes Duration                
0-5 years          48.4 45.4-51.4 ref. 51.9 48.9-55.0 ref. 
6-10 years          56.0 52.2-59.8 <.001 56.5 52.7-60.3 0.057 
>10 years          67.4 64.7-69.9 <.001 64.7 62.1-67.3 <.001 
Note. Reference groups are year=2010, race/ethnicity=NH-whites, age=18-44 years, men, education= ≤12 years, marital status=single, usual provider=no, insurance 
status=uninsured, insulin use=no, and duration of diabetes=0-5 years. Bold font indicates statistical significance at P<0.05. All models adjust for state and year fixed effects. 
Model 2 adjust for predisposing factors. Model 3 adjusts for enabling factors. Model 4 adjusts for need factors. Model 5 adjusts for all factors. NH, non-Hispanic; CI, 








 This chapter summarizes findings and places them in the context of existing and future state of 
research and practice, given the study’s limitations and strengths. This research examined trends in eye 
examinations among U.S. adults (aged≥18 years) with diabetes, assessed racial and ethnic differences in 
eye examination rates, and assessed changes in eye examination rates in individuals with diabetes living 
below 138% of the federal poverty level (FPL) in states that expanded Medicaid compared to those that 
did not. This study utilized data from the 2010-2017 Medical Expenditure Panel Survey. Trend analyses 
and multivariable logistic regression analyses were used to answer two specific research questions: (1) 
Are there racial and ethnic disparities in eye examination rates among U.S. adults (age≥18 years) with 
diabetes across 2010-2017? (2) Is ACA Medicaid expansion associated with changes in eye examination 
rates among U.S. adults with diabetes living below 138% of the federal poverty level (FPL)? 
Summary of Findings 
Crude Trends and Racial and Ethnic Differences in Eye Examination Rates  
Studies on recent trends in eye examination rates examined by race and ethnicity are scarce in 
the literature. To the best of our knowledge, the present study is the first to examine trends in racial and 
ethnic disparities in eye examination rates among U.S. adults (age≥18 years) with diabetes across 2010-
2017. This study found no significant trends in crude eye examination rates for the overall study 
population or for non-Hispanic whites, non-Hispanic blacks, and Hispanics. Similarly, a study based on 
data from the 2001-2010 Behavioral Risk Factor Surveillance System (BRFSS) also found no significant 
trends in crude eye examination rates for the overall population, non-Hispanic blacks, or Hispanics, but 
found an overall decreasing trend in eye examination rates for non-Hispanic whites (Chen et al., 2014). 
Shi et al. (2014) found the opposite in their study based on 2002-2009 MEPS data: non-Hispanic whites 







67% reported in their study is consistent with our study’s rates of 64-66% indicating that the annual eye 
screening rates have remained relatively stable over time.  
 In unadjusted analysis of racial and ethnic differences in eye examination rates, the present study 
found that overall, the crude eye examination rate in non-Hispanic whites was significantly higher than 
the crude eye examination rates in non-Hispanic blacks and Hispanics. The findings in this study are 
similar to those of other studies in that crude eye examination rates were higher for non-Hispanic whites 
compared to Hispanics (Lee et al., 2006; Shi et al., 2014) and for non-Hispanic whites compared to non-
Hispanic blacks (Lee et al., 2006; Shi et al., 2014).  
 Adjusted Trends and Racial and Ethnic Differences In Eye Examination Rates  
This study used multivariable logistic regression to control for predisposing, enabling, and need 
factors while assessing trends and racial and ethnic differences in eye examination rates. Similar to 
unadjusted analysis, adjusted analyses found no significant trends in eye examination rates for the 
overall population or for non-Hispanic whites, non-Hispanic blacks, and Hispanics.  
 In the models adjusting for enabling and need factors, non-Hispanic blacks and Hispanics were 
less likely to report eye examinations compared to non-Hispanic whites. However, in the model 
adjusting for predisposing factors, Hispanics were the only group less likely to report eye examinations 
compared to non-Hispanic whites. This suggest that the predisposing model contains confounding 
factors that distort the relationship between the race and ethnicity and eye examination rates due to 1) 
their association with eye examination rates and 2) their uneven distribution among the racial and ethnic 
groups. For example, research has shown that black Americans display lower marriage rates than do 
other racial and ethnic groups (Bramlett & Mosher, 2001; Martin et al., 2014; Raley et al., 2015; Sweeny 
& Phillips, 2004) and high school dropout rates remain the highest among Latinos, followed by African-







proportion of Hispanics (45.7%) had <12 years education compared to non-Hispanic whites (13.5%) or 
non-Hispanic blacks (19.9%) and a greater proportion of non-Hispanic blacks (60.6%) were single 
compared to non-Hispanics whites (39.4) and Hispanics (43.6%) (see Appendix I). Additionally, both 
education and marital status were significantly associated with the outcome in adjusted models. 
Specifically, adults who were married had a 6.3 pps higher rate of eye examination compared to adults 
who were single (p=<.001) and adults with ≥12 years of education had a 9.8 pps higher rate of eye 
examination compared to adults with <12 years of education (p=<.001; Table 4.2). Therefore, in 
controlling for these factors, a more accurate relationship between and ethnicity and receipt eye 
examination can be observed.  
 In the model adjusting for all factors (predisposing, enabling, and need), no significant 
differences were found in eye examination rates by race and ethnicity. Our findings are consistent with 
Monnette et al.’s (2014) study of 2014-2015 MEPS data which also did not find significant differences 
in eye examination rates by race and ethnicity. A study of 2002-2013 MEPS data also found there was 
no association between race and ethnicity and receipt of eye examination in a model adjusting for age, 
sex education, insurance status, economic status, diabetes care measures, and vision and general health 
measures (Tran et al., 2017). However, our results differ from those reported in Chen et al.’s study 
(2014). In Chen et al.’s (2014) study of 2001-2010 MEPS data, their adjusted model was most 
comparable to our fully adjusted model in that it adjusted for eight out of nine of our predisposing, 
enabling, and need factors (did not adjust for duration of diabetes). In their adjusted model, race and 
ethnicity remained significantly associated with receipt of eye examination; non-Hispanic blacks and 









Medicaid Expansion Analyses 
 There have been limited prior studies examining the effects of the ACA on changes in eye 
examination rates. In this study, Medicaid expansion was not associated with changes in eye 
examination rates in any of the multivariable logistic regression analyses. In Chen et al.’s (2020) quasi-
experimental study using 2009-2017 BRFSS data, results of DiD  analysis (adjusted for age, sex, and 
race) revealed that Medicaid expansion was associated with a significant increase in eye examination 
rates for the 2014-2015 period but was no longer associated with changes in eye examination rates for 
the cumulative study periods of 2014-2016 and 2014-2017. The lack of association between Medicaid 
expansion and changes in eye examination rates could be influenced by changes in provider availability. 
With improvements in insurance access, there may not be enough eye care specialist available to meet 
the demand of the increased number of newly insured patients requiring eye examinations. Recent 
studies reported increased difficulty of obtaining a specialist appointment in 2016 compared to 2014 or 
2015 (Sommers et al., 2017) and significantly longer wait times for low-income adults in expansion 
states (Miller & Wherry, 2017). Limited eye care specialist availability is plausible considering that 
60.7% of counties in the U.S. are in the lowest two quartiles for ophthalmologist and optometrist 
availability (Gibson, 2015).  
Study Limitations 
 This study had several limitations. First, the MEPS diabetes care survey only collects 
information on the dilated eye examinations but does not collect information on other forms of diabetic 
retinopathy screening such as validated retinal photography used in telemedicine. However, dilated eye 
examination is still considered the gold standard for diabetic retinopathy screening, so the rates should 
be most relevant to quality of care for diabetes (ADA, 2019). Second, due to the phrasing of the 







year, it is possible to underestimate the prevalence of dilated eye examination. Respondents might not 
have obtained their annual eye examination at the time that the MEPS interview was conducted. 
Therefore, cases could be missed if the respondent obtained an eye examination following the MEPS 
interview. Third, MEPS does not include a measure for whether respondents have prediabetes or 
undiagnosed diabetes. As of 2018, 7.3 million adults (age≥18years) in the U.S. had undiagnosed 
diabetes and 88 million adults had prediabetes (CDC, 2020a). Therefore, underreporting of diabetes 
prevalence is possible. Fourth, if a large proportion of the study respondents enrolled in Medicaid prior 
to expansion, then the effect of Medicaid expansion might be underestimated. We partially controlled 
for this effect by including non-expansion states that likely had similar cross-sections of survey 
respondents and by including insurance status as a control variable in adjusted models.  
Public Health Implications 
 Although there are effective treatments available to prevent and even reverse vision loss from 
diabetic retinopathy, it still remains one of the leading causes of preventable blindness in the U.S. (CDC, 
2018; Cheung, Mitchell, & Wong, 2010; Leasher et al., 2016). It is important that diabetic retinopathy 
screening programs are tailored to target those at highest risk and who are least likely to obtain 
screening. In order to create a successful screening program, it is important to understand the factors that 
influence whether an individual obtains screening. This study provides evidence that trends in dilated 
eye examination rates remained relatively stable; racial and ethnic disparities in eye examination rates 
are no longer apparent after controlling for predisposing, enabling, and need factors, and Medicaid 
expansion was not associated with changes in eye examination rates.   
 The U.S. Department of Health and Human Services’ Healthy People goals of vision includes 
increasing the proportion of people who have an annual dilated eye examination to 58.7% for 2020 and 







the adult diabetes population has consistently met the 2020 goal. Although not significant, our study did 
find a slight downward trend in rates, so whether eye examination rates will meet the 2030 goal over the 
next decade is uncertain.  
 Although lack of health insurance has been identified as a major barrier to individuals obtaining 
necessary medical care including diabetic retinopathy screenings (Ellish, Royak-Schaler, & Passmore et 
al., 2007; Lu et al., 2016; Owsley et al., 2006; Paz et al., 2006; Shi et al., 2014; Walker et al., 1997), our 
analysis examining the role of Medicaid expansion on eye examination rates found no significant 
differences in eye examination rates between individuals residing in an expansion versus non-expansion 
states suggesting that increases in insurance access alone may not be sufficient in improving dilated eye 
examination rates. Our results based on fully adjusted DiD models showed that several of the 
predisposing, need, and enabling factors (i.e., age, education, marital status, has usual provider, 
insurance status, takes insulin, and duration of diabetes) were related to receipt of eye examination. 
Thus, future research on policies or programs aimed at addressing other influencing factors may be 
warranted to improve dilated eye examination rates.  
 For instance, health literacy regarding the need for a dilated eye examination was identified as a 
major barrier of diabetic retinopathy screening (Graham-Rowe et al., 2018; Liu & Swearingen, 2017; 
Piyasenya et al., 2019; Lindenmeyer et al., 2014; Srinivasan et al., 2017). The U.S. Department of 
Health and Human Services defines health literacy as “the degree to which individuals have the capacity 
to obtain, process, and understand basic health information needed to make appropriate health 
decisions” (Koh, 2010; ODPHP, 2020d). Persons with adequate health literacy are more likely to take 
responsibility for their health and for their family’s health (ODPHP, 2020d). Those at risks for reduced 
levels of health literacy include individuals with lower education levels and racial and ethnic minorities 







National Assessment of Adult Literacy (NAAL), almost half of adults who did not graduate from high 
school had low health literacy (Kutner et al., 2006). Our study saw that a significantly higher proportion 
of Hispanics compared to non-Hispanic whites had <12 years of education (45% vs 13%, p<.001) (see 
Appendix 9). Previous research supports that Hispanics have the highest high school dropout rates 
followed by blacks and whites (Kena et al., 2015). Therefore, it is probable that the difference in 
education level may be associated with the respondents’ level of health literacy regarding diabetes care 
and thus, contribute to the respondents’ non-adherence to diabetic retinopathy screening guidelines. 
Interventions aimed at improving patient knowledge regarding diabetic retinopathy and screening should 
be tailored to match different levels of education.  
 In addition to low health literacy, the lack of a health care provider’s recommendation for eye 
screening has also been identified as a barrier of diabetic retinopathy screening (Dervan et al., 2008; 
Kashim, Newton, & Ojo, 2018; Van Eijk et al., 2012). Primary care providers play a vital role in 
diabetic eye care as they can educate, recommend, and refer patients to eye specialist for screening (Liu 
& Swearingen, 2017). Primary care providers do not directly perform diabetic retinopathy screening but 
may have greater access to patients with diabetes than do eye care providers because at least 90% of US 
patients diagnosed with diabetes are treated by primary care physicians (Davidson, 2010; Liu & 
Swearingen, 2017). Therefore, they can influence more patients with diabetes to have eye screening 
through their recommendation. However, limited access to a usual primary care provider can reduce 
opportunities for screening recommendations. Our study found that a greater proportion of persons with 
a usual provider had an eye examination compared to persons without a usual provider (66.3% vs 
54.5%, p=<.001; Table 4.2). Interventions should target improving access to primary care providers for 
vulnerable populations that will benefit most from diabetic retinopathy screening. Practices to improve 







effective resources for patients, and helping patients find the least expensive options for transportation, 
insurance, and medication (Toscos et al., 2018). 
Opportunities for Future Research 
 Although screening as met the 2020 target and appears to remain stable over the past decade, 
improving screening rates continues to be a priority objective of 2030 healthy people. Improving 
screening rates will require more creative methods for health care delivery as access to care continues to 
be a barrier for many. Access to eye care specialists has been identified as a barrier of diabetic 
retinopathy screening (Lindenmeyer et al., 2014; Liu & Swearingen, 2017) and is also often limited by 
geographic, economic, cultural, educational, and other factors (Cavallerano & Conlin, 2008; Hartnett, et 
al., 2005; Gower et al., 2013). Studies have shown that residents in areas with a low density of eye care 
professionals are less likely to have an annual eye examination (Chou et al., 2012; Resnikoff et al., 
2012). A study of BRFSS data linked to the Area Resource File found that individuals residing in 
counties with less than 20 eye care professionals/100,000 people were less likely to report having had a 
dilated eye examination in the past year than those with 20 or more ECPs/100,000 people (Chou et al., 
2012). Further, analyses of data from the 2011 Area Health Resources File demonstrated that 24.0% of 
the 3143 US counties had no ophthalmologists or optometrists (Gibson, 2015) and many of these 
counties are rural areas where long travel distances have been shown to negatively affect adherence to 
diabetic eye screening (Chen et al., 2020; Liu et al., 2018) supporting the notion that the distribution of 
optometrists in the US is not conducive to the coverage of remote areas (Gupta et al., 2017).  
 Telemedicine screening for diabetic retinopathy has the potential to provide screening services to 
areas where optometrists or ophthalmologist are scarce, thus, enabling individuals who live in these 
areas to have greater access to diabetic retinopathy screening services (ADA, 2019, p. 129). This 







an appropriate alternative method for diabetic retinopathy screening (ADA, 2019, p. 129). Studies 
evaluating the United Kingdom’s Diabetic Eye Screening Program (DESP), which uses telemedicine to 
enable broader coverage, have shown that the program was successful in increasing the annual uptake of 
diabetic eye screening (Public Health England, 2017; Scanlon, 2017; Sim et al., 2016). As telemedicine 
programs continue to evolve and expand, future studies should 1) examine the effects of telemedicine on 
uptake and adherence to diabetic retinopathy screening guidelines, particularly in vulnerable populations 
and areas with a low density of eye care specialists, 2) examine the costs-effectiveness of the 
telemedicine approach compared to the traditional optometry/ophthalmology approach, and 3) how 
effective is it in detecting and preventing adverse eye outcomes.  
 Prior studies and the present study used survey data to examine the association of Medicaid 
expansion on changes in eye examination rates in low-income adults with diabetes. However, the use of 
other data sources (e.g., administrative records) to examine this topic would enhance this body of 
research. Future research could examine changes in visits to eye care specialist, changes in eye care-
related provider visits, costs and reimbursements in diabetic adults residing in expansion versus non-
expansion states 
Conclusions 
 Diabetic retinopathy is a treatable condition if caught early, yet many of individuals forego 
screening, which can lead to the development of vision loss and/or blindness. This study provided 
critical insight into the present trends (8-year avg rate: 65.0 %) in diabetic retinopathy screening that 
have remained relatively stable across 2010-2017, how those trends measure up to the national vision 
care targets of 58.7% (2020) and 67.6% (2030), and seemingly no differences in diabetic retinopathy 
screening between non-Hispanic whites, non-Hispanic blacks, and Hispanics when adjusting for 







provider), and need factors (insulin use, duration of diabetes). Additionally, it provided insight on the 
effects of Medicaid expansion on eye examinations in diabetic adults living below 138% of the FPL. 
Based on the study’s findings, insurance coverage may be necessary to access regular eye care among 
diabetic patients, but it may not be sufficient. Continued advancement in the delivery of screening for 
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Appendix D. Adjusted trend in eye examinations for U.S. adults (age ≥18) with diabetes: MEPS 2010-








E  Adjusted Model with Race and Ethnicity*Insurance Status Interaction Term 
 AAP 95% CI AME p-value 
Race and ethnicity      
NHW 65.5 64.0-67.0 Ref. Ref. 
NHB 65.6 63.8-67.5 0.1 0.904 
Hispanic 64.7 62.3-67.0 -0.8 0.583 
Insurance status      
Uninsured 46.8 42.1-51.4 Ref. Ref. 
Insured 66.7 65.5-67.9 19.9 <.001 
NHW*Insurance Status     
NHW*Uninsured  44.4 38.1-50.6 Ref. Ref. 
NHW*Insured 67.0 65.4-68.6 22.6 <.001 
NHB*Uninsured 50.6 44.0-57.1 Ref. Ref. 
NHB*Insured 66.7 64.8-68.7 16.2 <.001 
Hispanic*Uninsured 53.0 48.0-58.0 Ref. Ref. 
Hispanic*Insured 65.6 63.1-68.0 12.5 <.001 
Note. All models were adjusted for year, age, sex, education, marital status, insurance status, economic 
status, have usual source of care, insulin use, and duration of diabetes. AAP, average adjusted 
prediction; AME, average marginal effects NHW, non-Hispanic white; NHB, non-Hispanic black; CI, 







 F  Adjusted Model with Race and Ethnicity*Economic Status Interaction Term 
 AAP 95% CI AME p-value 
Race and ethnicity      
NHW 65.6 63.9-66.9 Ref. Ref. 
NHB 65.5 63.5-67.5 0.1 0.967 
Hispanic 64.6 62.2-66.9 -0.1 0.546 
Economic status      
<138% FPL 62.3 60.3-64.3 Ref. Ref. 
≥138% FPL 66.2 64.9-67.5 3.9 <.001 
NHW*Economic status      
NHW*<138% FPL 61.1 58.4-63.8 Ref. Ref. 
NHW*≥138% FPL 66.8 65.1-68.5 5.6 <.001 
NHB*<138% FPL 63.9 60.9-66.8 Ref. Ref. 
NHB*≥138% FPL 66.0 63.5-68.5 2.2 0.273 
Hispanic*<138% FPL 65.5 62.4-68.5 Ref. Ref. 
Hispanic*≥138% FPL 64.3 61.5-67.1 -1.2 0.543 
Note. All models were adjusted for year, age, sex, education, marital status, insurance status, economic status, 
have usual source of care, insulin use, and duration of diabetes. AAP, average adjusted prediction; AME, average 










G  Likelihood Ratio Tests 
 Degrees of 
Freedom 
Chi-square p-value 
Trend Analysis    
Full vs Predisposing 6 553.12 <.001 
Full vs Enabling 8 644.64 <.001 
Full vs Need 8 782.42 <.001 
Medicaid Expansion Analysis    
Full vs Predisposing 5 197.27 <.001 
Full vs Enabling 8 200.80 <.001 








H  Sensitivity Analyses 
 
 AOR 95% CI P-value 
Treatment Effects    
Model 1    
Years since expansion 1.1 0.9-1.3 0.263 
Model 2    
Expanded-1-year lag 1.1 0.8-1.6 0.508 
Model 3    
Expanded-2-year lag 1.3 0.9-1.8 0.099 
Note. Reference category for each treatment variable was no expansion. All models 
were adjusted for age, sex, race and ethnicity, education, marital status, insurance 
status, have usual source of care, insulin use, duration of diabetes and state and year 








I  Distribution of Population Characteristics by Race and Ethnicity 

















Age     <.001    <.001 
18 to 44 years 9.4 15.3 17.9  12.2 16.8 19.7  
45 to 64 years 43.4 48.4 49.0  44.0 47.7 45.6  
>=65 years 47.2 36.3 33.1  43.8 35.5 34.7  
Sex    <.001    0.027 
Men 51.8 42.4 47.5  39.1 34.4 41.2  
Women 48.2 57.6 52.5  60.9 65.6 58.8  
Education     <.001    <.001 
≥12 years 86.5 80.1 54.3  72.1 68.7 38.5  
<12 years 13.5 19.9 45.7  27.9 31.3 61.5  
Marital Status     <.001    <.001 
Single 39.4 60.6 43.6  33.3 21.5 45.6  
Married/partnered 60.6 39.4 56.4  66.7 78.5 54.4  
Economic status    <.001     
<138% FPL 17.2 32.8 35.9  n/a n/a n/a  
≥138% FPL 82.8 67.2 65.1  n/a n/a n/a  
Has Usual Provider     <.001    <.001 
No 5.4 6.9 88.5  8.4 8.1 12.5  
Yes 94.6 93.1 11..5  91.5 91.9 87.5  
Insurance Status    <.001    <.001 
Uninsured 4.4 6.6 16.3  6.9 10.0 21.6  
Insured   95.6 93.4 83.7  93.1 90.0 78.4  
Takes insulin     <.001    <.001 
No 69.5 68.3 68.9  64.0 61.5 65.0  
Yes 30.5 31.7 31.1  36.0 38.5 35.0  
Diabetes Duration     <.001    <.001 
0-5 years 33.2 33.4 34.9  32.0 32.0 32.7  
6-10 years 22.6 22.8 23.2  21.7 21.7 21.6  
>10 years 44.2 43.8 41.9   46.3 46.3 45.7   
Note. P<0.05 considered statistically significant. N/a, not applicable; NH, non-Hispanic;  FPL, federal poverty 
level 
 
 
